

PUBLIC HEARING HELD BY THE AD HOC ADVISORY GROUP
ON ORGANIZATIONAL SENTENCING GUIDELINES

BREAKOUT SESSION III

CONFIDENTIALITY, INTERNAL REPORTING
AND WHISTLEBLOWING

November 14, 2002

1:37 p.m. to 3:51 p.m.

Held at:

Thurgood Marshall Building

One Columbus Circle, N.E.

Judicial Conference Center

Washington, D.C. 20002

1 B-R-E-A-K-O-U-T S-E-S-S-I-O-N

2 MR. SWENSON: Welcome, everybody, to
3 the afternoon session, the topic of which is
4 called "Confidentiality, Internal Reporting, and
5 Whistleblowing." I think from discussions we've
6 had with some of the participants here that the
7 topics might be divided in a slightly different
8 language into sort of a category related to
9 whether or not clients' activities, if they're
10 engaged in vigorously, can end up hurting a
11 company, what we might call sort of for ease of
12 reference a self-guided privilege or immunity
13 bucket of issues. And then the second bucket of
14 issues being internal reporting, mechanisms for
15 accomplishing that, alternatives that might not
16 be mentioned in the sentencing guidelines for
17 effectively creating internal reporting
18 mechanisms and issues relating to the
19 confidential source protection. The dilemma of
20 companies in many ways is not being able to
21 promise confidentiality to employees even though

1 they would like to promise confidentiality to
2 employees that raise issues. That's sort of, I
3 think, kind of roughly the topic areas.

4 I want to make this very interactive
5 in discussion, and let me propose that we start
6 off by identifying ourselves for the public
7 record. As you know, this is being transcribed.
8 This will also allow sort of a sound test for our
9 audio expert as well. I'm Win Swenson. I am a
10 partner in Compliance Systems Legal Group, a
11 principal of Integrity Interactive, and a member
12 of the Sentencing Commission's Advisory Group that
13 issue those guidelines.

14 MR. HOWARD: Do you want to go around
15 this way?

16 MR. SWENSON: Whichever way you want
17 to go.

18 MR. HOWARD: I'm Chuck Howard. I'm a
19 partner in the Hartford law firm of Shipman &
20 Goodwin, and I'm also a member of the Advisory
21 Group.

1 MR. SWENSON: Why don't we go this way
2 then.

3 MR. HOROWITZ: I'm Michael Horowitz.
4 I'm a partner at the Washington office of
5 Cadwalader, Wickersham & Taft. I'm
6 also a member of the Advisory Group and
7 recently departed from Justice Department's
8 Criminal Division.

9 MR. GOLDSMITH: Michael Goldsmith,
10 former member of the Sentencing Commission,
11 presently a law professor at BYU.

12 MR. GNAZZO: Patrick Gnazzo, Vice
13 President of Business Practices at United
14 Technologies Corporation.

15 MR. JOHNSON: Ken Johnson. I'm an
16 independent consultant in ethics and policy. I'm
17 here as a coordinator for loose group of what
18 we'd call Coalition for Ethics and Compliance
19 Initiatives. We've done some work in this area
20 for years.

21 MR. SWENSON: Why don't we then -- we

1 have some people here who are observers, and
2 they're welcome to participate. I think what I'm
3 going to suggest is if there's a time you want to
4 make a comment, we'll identify you. Let's
5 identify the invited --

6 MR. LARSON: Sure. Yeah, I'm Charles
7 Larson, United States Attorney for the Northern
8 District of Iowa.

9 MR. SWENSON: Okay. Thank you. And
10 Joe on the phone.

11 MR. MURPHY: Yes, I'm Joe Murphy. I'm
12 a partner in Compliance Systems Legal Group, a
13 principal in Integrity Interactive, and also
14 co-editor of "Ethikos."

15 MR. SWENSON: And Joe is calling in
16 from Australia. He can be with us for a limited
17 period of time, and I think what we've agreed to
18 do is to start off with Joe making some initial
19 remarks followed by Commissioner Goldsmith and
20 then perhaps we'll take a bit of a time out to
21 discuss some of those issues pretty much, like,

1 to get the views or reactions of the -- of Chuck
2 Larson from the U.S. Attorney in northern Iowa.
3 Then we'll move onto our other witnesses after
4 that, and we certainly can come back to the
5 initial topics after we've gone through sort of
6 the second round.

7 So, Joe, why don't you kick things
8 off.

9 MR. MURPHY: Fine. The topic that I'm
10 going to talk about -- there's several elements
11 of this. One is the chilling impact to the
12 current system, how it can interfere with the
13 policy objectives of the guidelines. Now, I'll
14 talk a bit about the idea of the self-evaluative
15 privilege or really a form of immunity as part of
16 the solution for these problems. Also another
17 part of the solution is a potential form of limited
18 waiver so the government gets what it needs but
19 without sacrificing compliance efforts by
20 companies. And then the fourth --

21 MR. SWENSON: Joe, could you just --

1 Joe, can you hold on a second?

2 MR. MURPHY: Sure.

3 MR. SWENSON: Just, actually, one
4 other kind of point of order. I would say if any
5 of our -- anybody here would like to ask a
6 clarifying question or something along the way,
7 that I think will be certainly helpful and
8 welcome particularly since Joe is a disinviting
9 voice, you know, thousands and thousands of miles
10 away. So feel free to jump in.

11 Is that okay with you, Joe?

12 MR. MURPHY: That's fine, certainly.
13 And then the last piece of this is perhaps a few
14 words talking about what the Sentencing
15 Commission's role might be in bringing this
16 about. So the starting point is really talking
17 about this chilling effect, the type of -- from
18 my perspective, what the Commission has started
19 is really an extremely important policy
20 initiative. I think Enron, Worldcom, Tyco,
21 Adelphia, again remind us how important this is

1 and that compliance programs are so key. But I
2 think that these cases show how only real
3 empowered compliance programs can make a
4 difference. In, for example, Worldcom it was the
5 aggressive internal auditors who uncovered what
6 was going on. Whereas, people in other companies
7 did not take action, and I think we need to do
8 whatever we can to make these compliance efforts
9 real and with sufficient clout that they can make
10 a difference.

11 I think the risk of compliance
12 materials being used against a company is, in
13 practice, a weapon in the hands of those who are
14 antagonistic to compliance efforts, and you find
15 in companies -- for example, the litigation
16 lawyers. They drag their heels or resist an
17 expansive aggressive program. I've seen many
18 parts of compliance programs that are difficult
19 to do, if not even intimidating, things like help
20 lines, audits, monitoring, surveys, focus groups,
21 detailed reporting, but I believe it's those

1 aggressive efforts that are the real difference
2 between sham programs and real ones. It is,
3 though, an ongoing day-to-day battle to get these
4 things accepted, and, sadly, government is often
5 the strongest source of ammunition for those who
6 oppose taking those types of aggressive efforts.

7 But beyond the question of whether a
8 company will have a program, this chilling
9 concern is also an issue of what types of things
10 will be in the program. And in my experience the
11 inhibitions that come from this fear of
12 litigation can show up throughout the program.
13 It is the type of thing that I see in my daily
14 practice. And just to give you some examples of
15 this -- and I outlined some of these in an
16 article I did a few years ago called "Compliance
17 on Ice." One that I run into on a routine basis
18 is when I do compliance training, I will
19 essentially say to the employees, "Don't take
20 notes." What I say to them is, "Don't take them
21 unless you're so good that you feel confident

1 reading them to a jury," in which they all stop
2 taking notes. This is very bad advice from a
3 teaching point of view, but in my opinion really
4 necessary as a result of a case The Lucky Stores
5 case where training notes were actually used
6 against a company very effectively in litigation.

7 Similarly in codes of conduct, when I
8 give advice to people -- or what they can say
9 about the confidentiality of whistleblowers, I
10 have to remind them you simply cannot assure
11 confidentiality because of litigation. Even
12 though you have government agencies, the EEOC
13 comes to mind, which essentially says, look, we
14 want you to assure employees that they can call
15 in confidence, but, in fact, it's often the
16 government that's the first one who asks for this
17 type of information.

18 MR. SWENSON: Joe, you've already
19 shifted gears past Lucky Stores, but could you
20 just explain what happened in that case. What
21 happened during the training that -

1 MR. MURPHY: Sure. The Lucky Stores
2 case was an employment discrimination case. It
3 was in California, and, among other things, Lucky
4 Stores had instituted an employment
5 discrimination program where they brought in an
6 outside expert who happened to be a lawyer but
7 was not practicing as a lawyer. And the
8 technique this trainer used was to bring in
9 employees from the floor, from the operations,
10 and have them identify any and all discriminatory
11 comments, stereotypical references, that type of
12 thing that they had heard while they were working
13 there. And, of course, as you all know how
14 Murphy's law operates. Someone in the room took
15 detailed notes of everything that these people
16 said. The plaintiff lawyers apparently heard
17 about this and demanded the notes. This went to
18 the judge who said that absolutely the plaintiff
19 is entitled to them. When the plaintiff got
20 a hold of the notes, they said this is the smoking
21 gun, this is it. When the court wrote its

1 original opinion on this, it held that the
2 plaintiff should be able to allege punitive
3 damages and then cited these notes as a basis for
4 that. Interestingly enough, in her same opinion
5 earlier on, she'd noted without any comment that
6 when the company lawyers had found out about
7 this, they discontinued the training.

8 MR. SWENSON: And your observation on
9 that case is that the person conducting the
10 training was sort of asking for people to provide
11 this information during the course of the
12 training so that they could have a candid
13 discussion of what's going on and how to fix it.
14 Does that make sense?

15 MR. MURPHY: Exactly so, and in the
16 compliance field you find that the best learning
17 examples are real cases, real things, things that
18 come from the company. Employees identified the
19 notes with that. It has the greater impact. At
20 the same time what you find is the lawyers who
21 understand the litigation system will say, well,

1 gee, it may be a great idea but you can't do it.
2 We can't have that type of information out there
3 and made available for use against us in
4 litigation.

5 MR. SWENSON: Okay. Thank you.

6 MR. MURPHY: And part of my fear is
7 always I may -- I may say something in training
8 and an employee may write down only part of what
9 I've said and then have some comment that could
10 be used against the company.

11 Another area where I've see this type
12 of resistance is something as simple as preparing
13 a list of dos and don'ts. I've actually had a
14 company lawyer say that he never does that
15 because they can be used against you. As you
16 know, I'm involved in online training. One of
17 the things we do in that online training is we do
18 not record the scores of employees on the
19 quizzes. We only report that they successfully
20 completed the training, again, for the same
21 reason. Not publicizing the results of

1 discipline. Companies typically will not say
2 anything about discipline, will not say anything
3 about specific cases and action taken against
4 employees for fear of use in litigation. But, of
5 course, the issue is how can discipline deter
6 anybody if nobody knows about it, nobody knows
7 what's happened.

8 Not sharing the results of compliance
9 audits and investigations because those types of
10 things can be used against, and I mentioned the
11 point that truly -- the real cases, the best
12 examples of -- a great example of this was the
13 recent video put out by GE, which is quite
14 striking. It uses actual cases. It's very
15 effective, but you'll note in that video the
16 actual cases are all things that have happened
17 quite some time ago, and companies generally just
18 will not use something that is current.

19 The whole issue --

20 MR. SWENSON: Sir, if I could just
21 jump in again to just make sure that we're trying

1 to hear what you're saying.

2 MR. MURPHY: Sure.

3 MR. SWENSON: Your point is that,
4 again, being able to have a very candid
5 discussion about what's going on in terms of
6 compliance inside of your company is beneficial,
7 but areas internally always push back -- have
8 candor about those kinds of issues because once
9 this information is generated in writing or
10 circulated too widely within a company with risk
11 -- there is a risk created it can be used outside
12 the company, against the company.

13 MR. MURPHY: Exactly. And the
14 judicial privileges that we deal with,
15 attorney-client and at this litigation present
16 work product, are very easily waived. And if you
17 do that type of publication of them, even within
18 the company, there's an enormous risk. I'd add
19 another point to this that the lawyer who gives
20 that advice is not being irresponsible. In fact,
21 I would submit that the lawyer who fails to give

1 that advice is engaged in malpractice because you
2 have to warn your client of the litigation risk
3 of what you're doing.

4 MR. HOWARD: But the -- this is Chuck
5 Howard. The chilling effect that you're talking
6 about is that the threat of disclosure actually
7 changes -- it changes for the worse the way
8 companies handle internal training discipline,
9 auditing, and consideration of whether they're
10 law abiding. Is that what you're saying?

11 MR. MURPHY: Whether they're going to
12 do those things. Not whether -- obviously not
13 whether they'll obey the law, but efforts to
14 assure that they are. The management efforts.

15 MR. HOWARD: Well, then --

16 MR. MURPHY: I'd add one other caveat
17 to that, which is where I -- I do make the
18 difference in my own view from the view of many
19 other people. I don't see the issue so much as
20 secrecy as it is misuse of the materials against
21 the company.

1 MR. HOWARD: My question was leading
2 up to the question, do you think it has a
3 chilling effect on the companies' ability to find
4 out whether it is -- it or some agents of the
5 company or organization are engaged in illegal
6 activity?

7 MR. MURPHY: Absolutely. Absolutely,
8 it does. You'll find in companies that do
9 audits, for example, that the -- the inclination
10 is always to do process audits, not substantive
11 audits because in the process audit you can look
12 to see whether the program is working. In the
13 substantive audit, you have exactly that risk of
14 the material being used against [you]. Another thing
15 you see is that where this work is done, often
16 times it is done in control by lawyers rather
17 than having managers do this type of work because
18 that gives you the ability to at least argue
19 attorney-client privilege. It also gives you
20 much more control over how things are
21 articulated.

1 MR. GNAZZO: Joe, this is Pat Gnazzo.
2 I guess I would like to make one point with
3 respect to your argument on secrecy. More to a
4 company that is -- that has an established
5 program and does all the things that they should
6 be doing with respect to the sentencing
7 guidelines, what we've developed is a road map
8 for third parties, in effect, to look at our
9 audit plans, to look at our audit programs, to
10 look at our investigative reports, to look at our
11 allegation reports, to look at our programs with
12 respect to privacy for our employees to bring
13 things to the attention of management. So it's
14 not a matter of secrecy as much for a corporation
15 as that we have developed for all intents and
16 purposes a very strong road map for third-party
17 litigators to go after us with respect to
18 everything that they know we're doing in order to
19 prevent the things -- the various things that we
20 want to prevent as far as the commission of any
21 kind of illegal activity. And that is a concern

1 for any corporation when they develop that kind
2 of road map.

3 MR. MURPHY: I agree with that. And
4 another element of this is if you have a really
5 robust program and you have a company that's
6 staffed by normal human beings who make mistakes,
7 it's not just a fear that the company has
8 committed some nefarious act and now will be
9 uncovered. It's that you have a great deal of
10 potentially embarrassing personal information
11 about people, about activities in the
12 corporation. And once you get in litigation, all
13 of this is going to be in the hands of
14 plaintiffs' lawyer who's going to use that very
15 effectively to essentially extract money from the
16 company.

17 Well, I'd like to touch for just a few
18 minutes on some possible solutions to this
19 dilemma, and one of these is something that's
20 called a self-evaluated privilege, really a
21 proposal to provide immunity from use and

1 discovery against companies for the compliance
2 efforts. I drafted a model of this years ago in
3 a predecessor publication to "Ethikos." The
4 CECI has worked on this, and I think it really
5 looks at a couple fundamental points. One is
6 that for litigation purposes, compliance efforts
7 really should be treated as if they do not exist.
8 A key point about any privilege is --

9 MR. HOWARD: You're talking about
10 third-party litigation?

11 MR. MURPHY: Yes. For any privilege
12 that it needs to be certain and sure and not ad
13 hoc. And as the Supreme Court said, I think, in
14 the Upjohn case, an uncertain privilege is
15 really a little better than no privilege at
16 all. And I know from experience, if it's
17 uncertain no one will rely on it, and it
18 really will do nothing. It will just be a tool
19 for litigation but not something that affects
20 behavior.

21 Now, as you may know, I'm very much a

1 skeptical. I really don't believe in relying on
2 the good faith of people in corporations or
3 anyplace else. So for me any type of privilege
4 really needs to be conditioned on good faith, and
5 I see two key elements to this. One is, it only
6 applies if you fix what you find. This to me
7 says there's a key check on good faith and it's
8 found in the State Environmental Statutes. The
9 only protection you get is if when you find a
10 problem you fix it. The other is a requirement
11 that there be some disclosure to the government,
12 but only if the government has a good disclosure
13 program like the Antitrust Division's program.
14 And I see these two elements as key to keeping
15 all of this activity on the -- on the up and up.

16 I would also provide that these
17 benefits only occur for companies that have
18 compliance programs, that have followed the
19 guidelines' model. I see this type of protection
20 as really recognizing that those who do this type
21 of work in companies really are doing society's

1 work in doing so. And in this type of
2 legislation, what we'd be talking about is not a
3 privilege but a form of immunity that material
4 could not be used against a company -- but a key
5 difference between privilege and immunity in this
6 concept is you don't have easy waiver and, most
7 importantly, you don't have a requirement that
8 the material be kept confidential in the company.
9 If you're trying to protect attorney-client
10 privilege, the essence of that is
11 confidentiality. You keep it as closely nailed
12 as possible and only have access by a few people.
13 Whereas, in a compliance program, publicity is
14 key for it to be effective. You want to -- you
15 want to get the message out.

16 Another piece of this solution that I
17 see is something that's called a limited waiver.
18 I think there's strong policy reasons to favor
19 voluntary disclosure to the government where
20 violations are found. Among other things, it
21 acts as a check on corporate honesty about their

1 compliance efforts, but the big dilemma here is
2 that waiver of existing privileges unfairly lets
3 outside adversaries get a free ride on the
4 company compliance office or company counsel's
5 investigative work. Because once you disclose to
6 the government, you've disclosed to everybody, at
7 least in the view of most courts. And the
8 lawsuits protection really exposes those who are
9 responsible for the compliance program to
10 ridicule for being so naive as to trust the
11 government not to disclose this material.

12 If you have a form of limited waiver,
13 it is a real win-win answer as I see it. The
14 enforcement agency gets everything that it needs
15 to do its job. The company retains its privilege
16 for every other purpose, and third parties really
17 lose nothing. They're right where they would
18 have been if the company had not done the
19 compliance work. That is, if a third party wants
20 to sue my company, they have to do their own
21 work. They do not get a free ride on the

1 compliance program. So I see those two elements,
2 some type of privilege and immunity and some type
3 of limited waiver as key elements.

4 MR. GOLDSMITH: Joe?

5 MR. MURPHY: And it takes -- yes, I'm
6 sorry.

7 MR. GOLDSMITH: Joe, Michael
8 Goldsmith. With respect to the immunity -- and I
9 intend to discuss that a bit when I chat as well.
10 But do you see that immunity running only to the
11 company or also to the employees?

12 MR. MURPHY: Well, that's a difficult
13 issue that's also tied in with this issue of
14 immunity. And once you get the individual
15 involved, you start creating degrees of conflict,
16 issues of when one can waive and the other not.
17 I would view this essentially as the
18 organization's -- it's the organization's
19 responsibility to do self-policing. It's the
20 organization's ability to control disclosure of
21 this material in general. Now if we're dealing

1 with the whistleblower scenario, that I would
2 view as an exception. There I think society has
3 an interest in protecting the identity of the
4 individual whistleblower, so that's the one area
5 where I would say yes, that should be worked out
6 as a joint protection so the individual can rest
7 assured when they make that difficult call that
8 their identity to the maximum extent possible
9 will be protected.

10 MR. GOLDSMITH: I think that I share
11 your view. Although, the obvious problem is that
12 if an employee knows that he or she is not
13 immunized, they're going to be less likely to
14 work with the program in a cooperative fashion.

15 MR. MURPHY: Well, I suspect that
16 immunity issue -- the more important immunity
17 issue to the employee is not -- I don't think
18 it's so much disclosure. It's a real genuine
19 article. It's immunity. That's one of the
20 reasons why the Antitrust Division's program has
21 been so effective, their disclosure program.

1 Because when a company discloses, the individuals
2 who cooperate are also protected. But that gets
3 to the issue -- to me, it gets more to the issue
4 of the type of disclosure program.

5 MR. GOLDSMITH: Okay.

6 MR. MURPHY: Just a couple comments on
7 possibilities of the Sentencing Commission in
8 this area. I think one is that the Commission
9 could play a role as a key clearing house for
10 compliance-related information data, information
11 from the enforcement side about how they treat
12 companies with compliance programs. I think the
13 Sentencing Commission stands in their role of
14 possibly being an honest broker in this. For
15 example, perhaps pulling together a conference
16 among enforcement and compliance people. There's
17 a model for this. The Healthcare Compliance
18 Association did this type of thing with HHS and
19 the Department of Justice and the HHSIG.

20 Another thought to consider here is
21 the need for some separate government liaison

1 office that operates for this purpose of
2 promoting compliance, and, ironically, it's a
3 lesson that's taught by item two of the
4 sentencing guidelines. If you want something
5 done, you really have to make it someone's
6 specific job to do that. I think that anything
7 that promotes strong bonds for any disclosure
8 program is critical. Again, there's
9 inconsistency among the different agencies. The
10 Antitrust Division probably has the strongest
11 disclosure program. Other agencies look at that
12 program and say, well, gee, we can't do that
13 because that's antitrust and this is something
14 else. EPA has done some work in this area, but I
15 think there's a need for a more consistent
16 approach in government and something that draws
17 on the lessons of the success of the antitrust
18 divisions program.

19 And perhaps the Commission could
20 actually propose legislation that really captures
21 the policy significance of voluntary compliance

1 efforts, helps to move the courts away from the
2 traditional suspicion they've had about
3 privilege, and even suspicion about compliance
4 programs, at least in some court opinions, I
5 believe. Perhaps helping to establish baseline
6 standards for enforcement efforts in this area
7 and really to set a tone for all enforcement
8 agencies to recognize that these voluntary
9 efforts are important and to do as much as
10 possible to promote these programs and really
11 rigorous programs, not the weak paper programs
12 that we see in a company like Enron. But to
13 really promote aggressive programs that help
14 truly prevent and detect misconduct.

15 So those are my thoughts for the
16 Commission, my thoughts from Australia at least.

17 MR. SWENSON: From down under.

18 MR. MURPHY: From down under.

19 MR. SWENSON: Thanks, Joe.

20 MR. MURPHY: Melburn actually.

21 MR. SWENSON: Thanks, Joe. We'll

1 obviously be coming back to you.

2 Chuck, can I just clarify for a
3 second?

4 MR. HOWARD: Yes.

5 MR. SWENSON: When you and I had
6 spoken, my understanding was that you didn't have
7 anything that you wanted to particularly come in
8 and say off the bat, but that you were more than
9 willing to react and give your thoughts as we
10 went along.

11 MR. LARSON: Sure, yeah, that's right.
12 And I just point out I think I'm an official
13 spokesperson for the Department of Justice, but
14 I'm here as one of many U.S. Attorneys to discuss
15 some -- what might be good or not good. With me
16 is Sean Berry. He'll introduce himself, and he
17 came to Iowa to Cedar Rapids. It's our good
18 fortune to have him because he came from
19 California where he the head of their Major
20 Crimes section of 32 or 35 attorneys there
21 with him. So he has a good background, and I

1 asked him to join us to discuss our (inaudible).

2 MR. SWENSON: Okay. And obviously
3 feel free at any point to jump in. I'm going to
4 -- I think perhaps after Michael has a chance to
5 talk to us, we'll come back to you a little bit
6 and ask you some of your reactions in what we've
7 heard.

8 MR. LARSON: All right.

9 MR. SWENSON: But is there anything
10 you want to add?

11 MR. LARSON: I think we have one
12 question for Mr. Murphy about his limited waiver.
13 It might work when he's testifying in court if
14 it's a criminal case, but would prevent the civil
15 attorney that worried about the allegation being
16 there hearing all that testimony.

17 MR. HOWARD: The government's civil
18 attorney?

19 MR. LARSON: Yeah, the government or
20 some other third party. That is one of the major
21 issues in the question. What about a third-party

1 attorney hearing that testimony?

2 MR. MURPHY: Okay. You're asking
3 about, let's say, something goes to some type of
4 proceeding?

5 MR. LARSON: Yes.

6 MR. MURPHY: Although, I'd just add --
7 you'd know far better than I, but at least
8 typically for a major company that does a
9 voluntary disclosure, there's not likely to be
10 much of a proceeding. They're typically going to
11 settle. I mean, my experience with the major
12 companies is the only ones that are going to go
13 to litigation is if it's a death penalty if they
14 don't, such as Anderson. So the risk of a
15 plaintiff's lawyer sitting in court hearing the
16 proceeding, at least in my experience, are
17 relatively minimal because it just doesn't
18 happen. Any company that's going to disclose, at
19 least major companies, are typically going to
20 settle.

21 But the issue for me -- and you've

1 touched on a difficult one that certainly some
2 degree of information may be made public as part
3 of the proceedings, and a third party could use
4 that information to go after other information.
5 But what the immunity would do is bar them from
6 using anything in an official basis, using
7 anything against the company that was disclosed
8 on this basis. In other words, they could not --
9 they could not use documents, use information,
10 use material that was from the compliance program
11 as, for example, an admission against interest.

12 MR. BERRY: I think -- I think from --
13 this is Sean Berry speaking. I think the issue
14 might arise more under your limited waiver
15 scenario where the information is provided to the
16 United States, the law enforcement side. Let's
17 say that the corporation is not ultimately
18 charged but individuals are and the individuals
19 go to trial as often happens. It's in that trial
20 where the stuff that under your limited waiver
21 issue comes out in the open, and then it's there.

1 So any third-party attorney sitting in the
2 courtroom can sit there and learn what they need
3 to bring about the case that you fear.

4 MR. MURPHY: That's certainly true.
5 What they can't do is request additional
6 information of that sort. You, for example, are
7 not likely to use an entire hot line log in a
8 company. You may pick out the particular points
9 you need to make your case, but the great
10 nightmare in this field is once a company
11 discloses -- you know you can't disclose a
12 little. If you disclose part, you disclose all.
13 And the nightmare is that the plaintiff's lawyer
14 then has access to all of this information and
15 it's going through, for example, all the audits,
16 all the help line logs, all the investigations in
17 getting access to that material. Whereas, what
18 you just described, yes, the plaintiff's lawyer
19 can take notes on the things that surface in
20 court and use that for their analysis, but they
21 cannot go to court and say that I'm entitled to

1 that audit report because it's already been made
2 public, so, therefore, there's no privilege. So
3 that's the key distinction. It's basically
4 giving the company as much protection as it could
5 possibly get in that context.

6 MR. LARSON: And hope for narrow use
7 of the --

8 MR. MURPHY: But also keeping in mind
9 that under the concept that I'm talking about,
10 the company -- it's more likely the plaintiff's
11 lawyer is going to get that in a certain sense
12 because companies will no longer have this fear
13 of waiving privilege by using material. So they
14 will use materials, but they'll be able to use
15 them in their company, for example, on a selected
16 basis without this fear of kind of rolling up all
17 the information, that everything is now disclosed
18 because I disclosed even a little bit of the
19 program.

20 MR. HOWARD: Why is that? This is
21 Chuck Howard. Because that's a -- that's a logic

1 step that I missed. You started by saying you
2 need certainty on this, and then what we've now
3 just described is kind of an exception to that
4 certainty where some of the material is going to
5 be disclosed. Why would --

6 MR. MURPHY: Because the issue for me
7 is not disclosure. It's the use, and
8 particularly the official use in litigation. One
9 nightmare in this field is that the things that
10 you say can be used against you as an admission
11 against interest. If you do a report that says
12 we did X, in the (inaudible) the plaintiff's lawyer
13 could take that into court and argue you were
14 stopped for saying you didn't do X because you
15 said it. It was an admission against interest,
16 and, therefore, you're going to be held to that.
17 You can, secondly, use it in court, use that
18 documentation as evidence against the company.

19 MR. HOWARD: And you don't think that
20 the same lawyer doing the same investigation is
21 not going to write down that under this

1 circumstance? Because I think --

2 MR. MURPHY: They can write it down.

3 The problem is they can write it down, but they
4 can't use it, for example, as an admission
5 against you or for cross-examination or for any
6 other purpose.

7 MR. HOWARD: They could use --

8 MR. MURPHY: That's what the immunity
9 concept would mean.

10 MR. HOWARD: Well, here's the other
11 question -- and it's been some time since you and
12 I've discussed this. But what concerns me is
13 that if the goal is to get certainty of
14 protection -- and I think you've correctly
15 absolutely diagnosed the nature of the problem.
16 But if this sort of limited immunity is premised
17 on a good faith use, why then wouldn't everything
18 come out in the third-party civil action in some
19 sort of preliminary discovery hearing where the
20 third party is challenging the disclosure -- the
21 prior disclosure to the government as not having

1 been in good faith? And in order for any sort of
2 fact finder to determine whether that prior
3 disclosure was in good faith, wouldn't all of the
4 facts and circumstances relating to what the
5 could know and how it dealt with it be disclosed
6 in that sort of a proceeding?

7 MR. MURPHY: We've actually been
8 dealing with that similar type of issue for a
9 long time in a self-evaluative privilege. The
10 good faith issue is very similar to the same
11 argument you run into in crime fraud, and I would
12 suggest the solution is a similar type of
13 approach where you'd have to have an in camera
14 proceeding. The burden would be on the plaintiff
15 to make that a prima facie case that you acted in
16 bad faith, and then that would have to be done in
17 camera. And if the court didn't agree with the
18 plaintiff --and keep in mind the legislation
19 that we talked about would have a strong policy
20 in favor of compliance work. If the court didn't
21 agree, then you would not have access to or the

1 ability to use that material.

2 MR. HOWARD: And it --

3 MR. MURPHY: So it would not -- it
4 would not promote a fishing expedition. In fact,
5 I think in the way I drafted the legislation, if
6 you did that you would actually have to pay the
7 cost of that if it were determined that you were
8 wrong and that material -- and this had not been
9 done in bad faith.

10 MR. HOWARD: Wouldn't the plaintiff's
11 counsel in this kind of hypothetical third-party
12 action want to engage in discovery perhaps broad
13 based described initially so that they would have
14 a whole series of documents and other
15 information?

16 MR. MURPHY: No, because you can't --
17 you can't --

18 MR. HOWARD: This is the last half,
19 not the first half.

20 MR. MURPHY: You can't do that, for
21 example, to establish crime fraud exception. You

1 can't do a discovery fishing expedition on the
2 basis that you want to see if there was a crime
3 -- that counsel was involved in a crime or fraud.
4 You don't get the discovery on that unless you
5 can establish a prima facie case to open it up.

6 MR. HOWARD: Sure. Now I --

7 MR. MURPHY: The same would apply
8 here. You can't do a fishing expedition to find
9 out whether it's done in good faith. You're
10 really going to have some basis for asserting
11 that it was in good faith.

12 MR. HOWARD: But the fishing
13 expedition or the discovery would be a
14 subterfuge. It would be kind of a discovery on
15 the general nature of the problem, you know, the
16 facts relating to the case?

17 MR. MURPHY: Right.

18 MR. HOWARD: And so you wouldn't be
19 able to cut that off?

20 MR. MURPHY: But the whole discovery
21 directed at the compliance program would be

1 what's off limits. That would be immune. You
2 could talk with people about what they were doing
3 but you can do that today. What you can't do is
4 notice a deposition of the compliance officer and
5 spend the day harassing the compliance officer
6 about what they were doing in the program.

7 MR. HOWARD: Let me change subjects
8 slightly. What you're proposing would not be
9 something that would be done with a recommended
10 change to the guidelines? It would be a separate
11 statute?

12 MR. MURPHY: That's how I view it,
13 yes. That would be the preferred remedy. The
14 jurisdiction of the Commission is limited. It
15 can't -- it can't restrict discovery, for
16 example.

17 MR. GNAZZO: Now, Joe, this is Pat
18 Gnazzo. At least based on our experience, if we
19 could split this in half from a criminal
20 proceeding with the Justice Department or any
21 federal official and go just to the third-party

1 civil action, one of our biggest problems in
2 dealing with third-party cases is explaining to a
3 judge over and over again the difference between
4 a public good versus the individual right. If
5 the Commission could at least establish some
6 guidelines with respect to public good, the need
7 to have a compliance program, the need to
8 establish those programs, to build those road
9 maps in order to continue to keep those programs
10 viable, then a judge at least has something in
11 looking at the scale in weighing a decision of
12 the individual right versus the public good to
13 have these kinds of programs and to limit access
14 to discovery or a fishing expedition. So what
15 I'm -- what I'm looking for is that in at least
16 in our experience we had to have our attorneys
17 spend an enormous amount of time dealing with the
18 public good, how our program works, how good our
19 program is, how solid it is, how we protect
20 individuals in order to get the judge to
21 understand that there is a public good in

1 balancing that individual right versus the public
2 good. If the Commission could make some
3 statements or some -- give some guidance to
4 federal judges with respect to public good, that
5 would be helpful because it gives them something
6 to hang their hat on.

7 MR. MURPHY: I think that's an
8 excellent point, and I think from what I've seen
9 judges typically see the number one good as
10 litigation and anything that interferes with
11 litigation as bad and even in the one area where
12 you see the most litigation on compliance
13 programs, employment discrimination. And you
14 have the Supreme Court in Ehlert [sic] and Farragher
15 talking about the importance of this type of
16 company work, you still find what seems to be
17 court nitpicking with, again, the presumption
18 that anything that interferes with litigation is
19 bad.

20 So I think to the extent that the
21 commission could make an even stronger policy

1 statement than it has in the past on just the
2 point you said about this being a matter of
3 public good. I think that would be an excellent
4 step.

5 MR. SWENSON: Although, Joe, I guess
6 absent some kind of legislative change, a policy
7 statement by the Commission, were it willing to
8 make one, would in a sense be arguing for a
9 judicial remedy that doesn't formally exist right
10 now, right?

11 MR. MURPHY: Yeah, that is right.
12 It's only going to go so far, and, of course,
13 it's also -- it's really -- as I indicated
14 there's a couple parts to this picture. One is
15 this whole privilege in immunity protection. The
16 other is really enhancing and making more
17 consistent the government approach to voluntary
18 disclosure, and, again, that's something where
19 the Commission can say something. Agencies may
20 or may not listen. But really to make some
21 progress in this, the (inaudible) is due by

1 legislation.

2 MR. SWENSON: Okay. Well, thanks,
3 Joe. Stand by, if you can. As I said, we're
4 going to withhold questions until after Michael
5 went. As you can see, we've just done that.

6 Michael, I think this is a good segue
7 into you.

8 MR. GOLDSMITH: Thank you. First I'd
9 like to point out that Win invited Joe to kick
10 things off. Joe kicked it off, caught the ball,
11 ran it back for a touchdown on his own, and is
12 about ready to kick it off again. Your comment
13 about the Commission taking a position on this,
14 Joe, makes me think about my departure from the
15 Commission. In 1998 people asked me what I was
16 going to do, and, of course, back then the
17 Commission was vacant for the most part. They
18 were having difficulty filling vacancies, so I
19 indicated that I was going to establish a
20 Sentencing Commission in exile in Park City,
21 Utah, where I lived. So if you want that

1 Commission in exile to issue a policy statement,
2 I can easily do that. There's not much of a
3 bureaucracy. It might not be much good, but
4 nevertheless I am prepared to go about.

5 This whole problem of self-evaluative
6 privilege in this context brings to mind the
7 adage, "No good deed goes unpunished." The
8 Sentencing Commission essentially made internal
9 compliance programs an essential aspect of
10 federal sentencing policy and then, in turn, if
11 it didn't create it, it certainly allowed to
12 continue the existence of a dilemma faced by
13 corporations that wanted to do the right thing to
14 be good corporate citizens. Whereby providing,
15 in effect, as Pat just pointed out a moment ago,
16 a litigation road map to anyone that gets access
17 to their compliance materials. The difficulty
18 then that we have here -- and what I propose to
19 do right now by my remarks is basically to
20 summarize, I think, much of what's been said, and
21 that may help you in terms of your record, Win.

1 The difficulty that we have is that
2 there is simply no certain way of protecting
3 compliance-related materials in this context.
4 The attorney-client privilege only goes so far.
5 It doesn't cover certain types of communications.
6 Certainly there is an enormous risk of waiver.
7 The work-product doctrine, likewise, doesn't
8 apply. The work-product doctrine, for example,
9 needs -- it is limited to matters prepared in
10 anticipation of litigation. And even if the
11 privilege or the doctrine does apply, it is
12 subject to a balancing test of sorts.

13 The self-evaluative privilege, at
14 least as of seven years ago, was not widely
15 recognized. To the degree that it was recognized
16 it tended to be applied mostly in a medical
17 context, and it too was subject to a balancing
18 test. With considerable assistance from Joe
19 Murphy and Win Swenson, years ago I wrote an
20 article dealing with this issue, and I made the
21 observation that the law right now is uncertain.

1 In preparation for this meeting, I have reviewed
2 the case law, none of which is cited in my
3 article. Although, my mother read it. The case
4 law continues to be very problematic. It is
5 mostly negative. When a company tries to assert
6 the equivalent of a self-evaluative privilege,
7 for the most part it's been rejected or it's been
8 confined to a medical context. Some --

9 MR. SWENSON: Michael, could I just
10 ask you to help us understand what the medical
11 context is and where it has been, in fact.
12 Because I think it may help us understand the
13 policy benefits --

14 MR. GOLDSMITH: The typical example
15 would be in a case of medical malpractice and the
16 hospital has its own internal review process to
17 determine what led to the "therapeutic
18 misadventure" and then plaintiff's counsel wants
19 to get access to the peer review committee's
20 findings to help make his case. So that's the
21 typical scenario which has come up, and there has

1 been some success in asserting the privilege in
2 that very limited context and you can see why.
3 Although, the similar reasons obviously apply in
4 a context under the guidelines. So I guess my
5 point is that the case law overall has been very
6 restrictive. It's been confined to a medical
7 context. And indeed in other situations, the
8 courts have said that even if we were to
9 recognize such a privilege, we would not apply it
10 with respect to a situation where the information
11 is sought by governmental agencies. There is a
12 recent Fifth Circuit case called "In Re. Kaiser
13 Aluna" of the fifth circuit in the year 2000 that
14 makes that point.

15 A continuing problem here is the
16 dearth of cases addressing the sentencing
17 guidelines, specifically with respect to
18 corporations in compliance programs because most
19 of the cases settled. So we just don't know how
20 courts will responds. This issue that we're
21 looking at really hasn't been addressed

1 specifically by any court in the context of a
2 guideline program. In light of that, we have as
3 I said very few cases and some of these cases are
4 examples of hard cases making bad law. I know in
5 one case, for example, a court declined to find
6 that a privilege applied to an internal
7 investigation conducted by a kennel club, so
8 these are not the types of cases that are going
9 to get a lot of attention by the courts and
10 produce the type of response from a policy
11 standpoint either from the courts or the Congress
12 that I think you're looking for.

13 I concur with Joe's view of immunity.
14 There needs to be some certainty here. Years ago
15 I thought that the position that Joe had taken on
16 this was that he was arguing for transactional
17 immunity, which I thought was too broad. It
18 appears that Joe's position now, and maybe was
19 then as well, but he endorses what is the
20 equivalent of use immunity. Nothing that
21 is provided by the program or

1 generated by the program may be used against it
2 nor anything derived therefrom.

3 The use of the immunity statute
4 federally has worked very well. The -- a party
5 needs to establish by the preponderance of the
6 evidence that any evidence it has available to it
7 in court was not, in fact, derived from immunized
8 testimony. The difference between the use of
9 (inaudible) that is on the table right now and
10 the Federal Use Immunity Statute is that the
11 Federal Use Immunity Statute does not have a
12 preclusion against civil application. Whereas,
13 what we have in mind here would.

14 I think that the present context or
15 climate rather from the standpoint of corporate
16 criminality and the public's heightened awareness
17 of it and certainly Congress' awareness of it.
18 We all know it's a serious problem. That this is
19 a good time for the Commission to take the
20 initiative and go to Congress and say that we
21 have established the importance of internal

1 compliance as part of the federal sentencing
2 policy. We, in fact, are undermining that very
3 policy by not protecting companies that make an
4 effort to comply with that initiative with -- the
5 initiative of internal compliance, and,
6 therefore, it's incumbent upon the Congress to
7 pass the equivalent of the Use Immunity Statute
8 in this context to protect these types of
9 materials. Only by adopting that type of measure
10 will you provide companies the requisite to
11 certainty that will ensure that the programs in
12 fact work and that people do make full
13 disclosure.

14 MR. HOWARD: When we talk about the
15 immunity statute, I'm assuming that you're
16 skipping over or reaching the conclusion that the
17 government is still going to make disclosure a
18 requirement. Are you -- and is the better way to
19 do that -- in other words, you've given up
20 fighting the battle on whether there's going to
21 be a required disclosure. You've conceded that

1 the government surely will continue to make
2 disclosure a requirement and so you're fighting a
3 battle on what use can be made of what we give to
4 the court? Is that --

5 MR. MURPHY: When you say
6 "disclosure," we're really talking about the type
7 of voluntary disclosure where there's a quid pro
8 quo. A company makes a disclosure, and as a
9 result of that there's typically something that
10 the government gives for that, for example,
11 exemption from prosecution or some lower penalty,
12 something of that sort. One thing that this
13 legislation would address, however, is the
14 current practice of basically conditioning of any
15 benefit on a complete and total waiver. That is
16 --

17 MR. HOWARD: Run that by again. I
18 missed that.

19 MR. MURPHY: I'm sorry?

20 MR. HOWARD: I missed that. Would you
21 run that by again?

1 MR. MURPHY: Yes. In the
2 attorney-client privilege area, for example, the
3 company does a voluntary disclosure. There are
4 some enforcement people in the enforcement community
5 who will say, look, as we sign of your good
6 faith, you must waive all privilege. What the
7 proposed legislation says is no, you can't do
8 that. If you have the limited waiver, then that
9 way -- the government cannot condition a
10 voluntary disclosure on giving up not only the
11 limited waiver but all privilege.

12 MR. GOLDSMITH: And I'm not sure that
13 I necessarily view disclosure as a prerequisite
14 to getting the benefit of the immunity. For
15 example, as I can see this, I would imagine that
16 if the program were immunized that the company,
17 for example, would not have to respond to a grand
18 jury subpoena. Just say listen, this is
19 protected. It's really a question of timing.
20 When does the immunity attach?

21 MR. MURPHY: Well, there's also -- I

1 mean, realistically there's a political question
2 of what the public is going to accept in terms of
3 privilege versus involuntary disclosure. I am a
4 big believer in voluntary disclosure if the
5 government keeps its end of the deal, if there is
6 some benefit from that. But certainly where
7 there's criminal conduct, I don't really see -- I
8 don't see a realistic possibility of legislation
9 that's going to permit someone to commit a crime
10 and then -- and then not disclose either the fact
11 of the crime or how they found out about the
12 crime. So at least in the criminal context, I
13 think that -- this is just my own political
14 expectation, that any type of immunity is going
15 to be conditioned upon some disclosure to the
16 government so the government can check on the
17 legitimacy of what the company did.

18 MR. GOLDSMITH: Well, Joe, clearly the
19 immunity ought not give the company a license to
20 commit a crime. In fact, the Supreme Court's
21 decision in Afflebaum (phonetic), an old perjury

1 case, said that the fact that you've been
2 immunized doesn't immunize you against a perjury
3 prosecution for conduct that you engaged in
4 during the course of your immunity grant.

5 MR. MURPHY: Sure.

6 MR. GOLDSMITH: The question I have --
7 I guess this follows up on Chuck's question then
8 is, how do you see this occurring from a timing
9 standpoint? When would the company actually
10 receive the immunity grant?

11 MR. MURPHY: The immunity would always
12 be there on the compliance work. It would
13 basically be saying that when the company has an
14 effective program under the guidelines, the
15 material that it creates, the work that it does
16 is simply not available for use in litigation.
17 In the sense that companies are doing
18 self-policing, so this is something that should
19 not be used against the company. But if a
20 company uncovers a criminal violation, it would
21 need to disclose that to the government. This

1 would be part of the definition of good faith,
2 and the only way you would get the immunity is if
3 you're always acting in good faith in the
4 program. So that's how I would see it.

5 The immunity is always there, but once
6 you found a criminal violation -- at least this
7 is one way to do this. That failure to disclose
8 the criminal violation to the government would
9 (inaudible) the whole argument that you were
10 acting in good faith.

11 MR. HOROWITZ: This is Michael
12 Horowitz. I have a couple questions just on the
13 use immunity question. Who would you envision it
14 applying to? Just the company or its directors,
15 CEO, CF - I mean, how does this layout?
16 Because someone has got to make the decision in
17 the company.

18 MR. MURPHY: The company. It would
19 apply to the company.

20 MR. HOROWITZ: No individuals?

21 MR. MURPHY: That -- yeah, the

1 individual piece would really -- would really
2 come up when you look at the form of immunity --
3 look at the form of the voluntary disclosure
4 program that the government has. But ultimately
5 it's the organization. It's the company that
6 this applies to.

7 UNIDENTIFIED SPEAKER: Michael, are
8 you in agreement? Do you have agreement?

9 MR. GNAZZO: I totally agree with Joe
10 and any corporate compliance ethics program, the
11 protection -- or the intent of the protection is
12 to the company, not to any one individual, and,
13 therefore, the use immunity should go to the
14 corporation if they were doing everything they
15 possibly could to protect. What's going on with
16 respect to a compliance program, the intent is
17 not to protect the individual who committed the
18 act. (Inaudible.)

19 MR. MURPHY: Yeah. But recognize that
20 as a practical -- as a practical matter, the
21 person suing that individual director is not

1 going to have access to this material because
2 material is immune from discovery and use. So
3 what we're saying, it's the organization's
4 privilege. The practical result is going to be
5 the government will get access to that but prior
6 plaintiffs are not going to get access to that
7 compliance material because it's off limits in
8 litigation.

9 MR. GNAZZO: But I wanted to go
10 further, Joe, in saying, however, you have to
11 understand that what you're doing in a program
12 like this is asking employees to come forward who
13 have knowledge of a particular event, and we try
14 to protect those individuals who come forward who
15 have knowledge of that particular event. So the
16 use immunity is the protection of the
17 corporation. But in doing that, we have to
18 protect the individual who came forward because
19 if we don't, I mess up my -- I mean, my program
20 is dead.

21 MR. HOWARD: Then you don't know where

1 it's going to go.

2 MR. GNAZZO: That's correct.

3 MR. HOROWITZ: Well, then that's --
4 this is why I'm asking that question because
5 stepping back we're pushing in this use immunity
6 idea with the privilege idea, and they're really
7 two -- I think there are two separate issues.
8 One is ensuring that disclosures can be made to
9 the government without third parties
10 benefitting from it.

11 MR. GNAZZO: Right.

12 MR. HOROWITZ: And the other privilege
13 concerns a company being willing to walk into the
14 government and not have it turn around and get
15 tagged with what they've disclosed. The problem
16 is the people who have -- I understand on the
17 privilege issue, the third-party issue, and what
18 the concern is. From the morning session, it
19 sounded as if at least the government
20 representatives on the panel understood that as
21 well and have as much trouble with that notion.

1 The question I have on the use
2 immunity side is there is going to be a
3 group within the company that has
4 to decide this question. And I guess the
5 question I have is, if the concern is companies
6 coming forward and making full disclosure, I go
7 exactly where Pat just was and say okay. You
8 also then want to encourage the employee to come
9 in and disclose and that would be high-level
10 people. We don't have to strain our
11 imaginations too far nowadays to think who that
12 might be and what examples we could use. And if
13 those individuals know that the company would
14 then essentially be obligated to waltz into the
15 government because it would be impossible to
16 explain why you didn't disclose if you got
17 immunity for your company. Why they would do
18 that if there were the high-level executives who
19 were involved with that wrongdoing and how do you
20 get to that next level and explain to the
21 individuals and make sure the individual who is

1 full of ideas and fostering and encouraging
2 people to disclose? Don't you just dry it up
3 down --

4 MR. GNAZZO: You're making -- you're
5 making a presumption that the disclosure is
6 always going to come -- or the majority of the
7 disclosures are going to come from the individual
8 that committed the act. And I have to honestly
9 tell you, our experience is not that the
10 individual who committed the act that is making the
11 disclosure. It's the individual who's being
12 asked to commit the act or the individual who
13 watched the act occur and is sitting there
14 pondering whether their careers are going to go
15 down the tubes because they bring something to
16 the attention of management. It's that
17 individual that I want to protect.

18 MR. MURPHY: Yeah.

19 MR. GNAZZO: Our policy says clearly
20 that the individual who committed or participated
21 in the act knowingly is going to be punished.

1 Now they may be punished by the government, but
2 they're also going to be punished by the
3 corporation because they've violated policies.
4 So my concern is to protect the individual who
5 wants to come forward who did not participate in
6 the act, who saw the act, and is uncomfortable
7 about coming forward because of fear of some form
8 of retribution.

9 MR. MURPHY: Yeah, I agree with that
10 very strongly. If I gave you a list of all the
11 senior executives that I know who voluntarily
12 disclosed that they did something wrong, it's a
13 remarkably short list. And I think their concern
14 is not what's going to be done with discovery.
15 It's the concern that they're going to have to
16 pay a price for doing something wrong, and none
17 of us can remove that. I mean, there's just no
18 way a company can say to someone, oh, good,
19 you're going to admit that you deliberately
20 engaged in environmental pollution that killed
21 people. Well, we'll assure you that X won't

1 happen to you. Companies are never going to have
2 that freedom, and I'm not sure that they should,
3 so it --

4 MR. SWENSON: We have a guest who
5 would like to make a comment, but I'd like to go
6 to our more official witnesses first and then
7 we'll come to you, sir, next. Okay.

8 MR. BERRY: I just had a question for
9 either Mr. Goldsmith or Mr. Murphy. Under this
10 immunity proposal -- let's take -- let's take a
11 hypothetical. A company does its internal
12 investigation and finds a crime that's been
13 committed. The government is completely unaware
14 of it, and the company self-reports to the
15 prosecutor. What can the prosecutor use under
16 your immunity? Is that -- is the prosecutor in a
17 position that they have to somehow prove that
18 they would have found out about the crime?

19 MR. MURPHY: No, no. Let me -- but
20 that's --

21 MR. BERRY: Let me finish.

1 MR. MURPHY: I'm sorry.

2 MR. BERRY: In order to prosecute the
3 corporation itself?

4 MR. MURPHY: Let me use the best
5 example, which is the Antitrust Division's
6 voluntary disclosure program. And then we
7 can go to another example, but in that example
8 you would go to the government. You do a
9 proffer. If the government buys in, your company
10 and its employees will not be prosecuted by the
11 government. Now the reason they do that is in
12 every antitrust case there's always another
13 potential defendant. So you get off, but they
14 nail someone else. In other programs you may
15 find that the deal is you do your disclosure and
16 you'll -- let's say you'll have to pay some
17 penalty, something bad will happen to you. But
18 in what I drafted, the government has full right
19 to use that material. The only thing that makes
20 that palatable for the company is the fact that
21 there has to be a voluntary disclosure program so

1 the company knows -- as long as it tells the
2 truth to the government, it knows what will
3 happen as a result of that disclosure.

4 But my view is you cannot limit the
5 use of the information by the prosecuting agency.
6 That limitation has got to be something that's
7 part of the voluntary disclosure program.

8 MR. BERRY: But that certainty comes
9 from then legislation that says self-reporting
10 grants immunity? Is that where you're going?

11 MR. MURPHY: It comes from whatever
12 structure it is that we set in place to make sure
13 that government agencies have effective,
14 well-thought out, strong voluntary disclosure
15 programs.

16 MR. BERRY: And how does the Holder
17 memo fall into that? Not strong enough for you?

18 MR. MURPHY: No, it's not. I'm always
19 -- I think one of the lessons of the sentencing
20 guidelines is the enormous value of some level of
21 commitment. The guidelines have been an enormous

1 success because of that. The Antitrust Division's
2 program has been an enormous success because of
3 that. You either give commitment or you don't.
4 If you don't do the commitment, you don't get the
5 response -- the same response from the regulated
6 community. If you give that commitment, that's
7 what causes the commitment from the other side.

8 So the critical element to me is not
9 having a soft policy that says, gee, we think
10 this is good and we might give you the benefit of
11 it. We'll consider lots of things, and we may
12 give you the benefit. That's not a commitment.

13 MR. BERRY: And so this is more the
14 carrot aspect of getting people to self-report?
15 Another alternative, though, would be to make it
16 more painful not to self-report, to go with the
17 stick to enhance the guidelines, right?

18 MR. MURPHY: Well, I guess that's
19 true, but, you know, in China it's a capital
20 offense to engage in any form of bribery and
21 China is rife with bribery. So if you can't

1 prevent crime by killing people for engaging in a
2 crime, I'm always skeptical about how much
3 leverage you can get by just increasing
4 penalties.

5 MR. HOWARD: Let me follow up on a
6 hypothetical, Sean, that you started. What if
7 everything that Sean said happened, the
8 prosecutor said that we're not going -- we're not
9 going to indict you. You're not going to be
10 charged, but it's very serious and I'm going to
11 walk this file over to the civil person and
12 action will be commenced civilly. Can -- what
13 happens to the information then? Can the
14 government not use --

15 MR. MURPHY: That's got to be part of
16 the voluntary disclosure program. The voluntary
17 disclosure program can't be a case of regulation
18 by ambush. It's got to be something where it's
19 predictable, and the disclosure has got to be
20 global. I mean, whatever it is has got to be
21 global. What I put in my draft legislation on

1 limited waiver is you can only -- the government
2 agency can only discourage the other agencies
3 that are subject to that same limitation.

4 MR. HOWARD: So, in other words, the
5 civil side could not use it?

6 MR. MURPHY: No, the civil side -- the
7 company -- the agency would have to draft its
8 disclosure program in a way that dealt with both
9 criminal and civil, and that would be dealt with
10 at the same time. I'm loath to start imposing
11 water tight compartments on government agencies
12 where they have to quarantine people and if you
13 look at this file then you can't do anything else
14 related to it. I'm loathed to impose that type
15 of administrative burden. The much smarter
16 approach is just to have a voluntary disclosure
17 cover the entire agency or cover the entire
18 enforcement community.

19 MR. GOLDSMITH: Joe, I want to get
20 back to the question that was put to us earlier
21 in terms of the company going to the U.S.

1 Attorney and saying that this is what we've done.
2 And the question put to us was whether the
3 information provided to the U.S. Attorney at that
4 time can be used against the government.

5 MR. MURPHY: And it could be used
6 against the company?

7 MR. GOLDSMITH: Yes, against the
8 company. Yes.

9 MR. MURPHY: You mean, you've already
10 done your voluntary disclosure --

11 MR. GOLDSMITH: Yes.

12 MR. MURPHY: Or you're at the proffer
13 stage?

14 MR. GOLDSMITH: Well, you come in and
15 meet with the U.S. Attorney and say this is what
16 happened. You're making your disclosure. The
17 question is whether the disclosed information may
18 be used against you as a basis for a criminal
19 prosecution or civil suit. Was this --

20 MR. MURPHY: Well, in the current --
21 in the current environment we all know the answer

1 to that. They can do whatever they want to do.

2 MR. GOLDSMITH: Right.

3 MR. MURPHY: What we're looking at is
4 a proposal that would say, first, there would
5 have to be a voluntary disclosure program. The
6 company would have the option. If they wanted to
7 go outside the voluntary disclosure program,
8 they'd be taking that risk. But the wise company
9 would go through the program, do its proffer,
10 negotiate whatever it could negotiate, and then
11 turn over the information so the government could
12 use it to verify that the company had told the
13 truth. But the government would already be
14 committed to what their -- what remedy they were
15 going to pursue, assuming the company had
16 initially told them the truth.

17 So could they use the information?

18 Yes, they could use it, but the remedy is limited
19 to what's -- what was negotiated in the voluntary
20 disclosure program.

21 MR. SWENSON: We have an observer who

1 is patiently -- do you still have your question
2 or did --

3 MR. SOLOW: I do.

4 MR. SWENSON: Can you identify
5 yourself?

6 MR. SOLOW: Yeah, my name is Steve
7 Solow. I was the chief of the Environmental
8 Crime Section at Justice. I'm now a partner
9 at the Washington, D.C., office of Hunton &
10 Williams and so in both my past and present
11 life this is a very big issue. I was wondering
12 about the issue - you said that the immunity
13 is always there if it's an effective program
14 under the guidelines, which almost seems like
15 we're the snake swallowing its own tail again
16 here because we get back to the question of
17 who's going to determine it's an effective
18 program under the guidelines for which it had
19 the immunity and are we then saying, you
20 know -- you were then getting back to
21 the question of who's going to make that

1 judgment, which my guess will end up being
2 litigated and actually the people deciding
3 whether effective compliance programs will be
4 federal judges.

5 MR. GOLDSMITH: But that's -- that's
6 like having the judge rule on whether there is an
7 attorney-client privilege in place. It's
8 comparable to that. The court gives a ruling and
9 --

10 MR. SOLOW: Right. Except judges have
11 been ruling on privileges for many, many years,
12 and their ability to determine whether a
13 company's sophisticated program was a "quite
14 effective program" sufficient to allow the
15 immunity to take effect is far more problematic.
16 And since what I recognize MR. GNAZZO was talking
17 about is the need -- what we're all talking about
18 is the need for certainty and the need of people
19 to have something they can rely on. And I just
20 don't know how you get that through this if we're
21 just going to shift the (inaudible) from one forum

1 to another. Maybe --

2 MR. MURPHY: I guess my response on
3 that is we've crossed that bridge ten years ago
4 when we elected to take this route of having
5 effective programs. That is really the key
6 indicator of whether an organization is a good
7 corporate citizen. Because of the nature of
8 criminal settlements, we haven't had ten years of
9 litigation. I would just mention that's shifting
10 now. You're seeing that litigation, but you're
11 only seeing it in the employment discrimination
12 area. I think to me the test of good corporate
13 citizenship, the test of good faith, is whether
14 companies have this program -- these types of
15 programs.

16 We probably do need to give more
17 direction to the judiciary that -- what the
18 Sentencing Commission had said really is American
19 policy, that it is critical for companies to have
20 these programs. And my view is we're going to
21 have to bite the bullet, that at some point

1 there's going -- somebody is going to have to
2 make judgments about whether these programs are
3 sham or real. You can set that standard wherever
4 you want. You can make it that the program has
5 to be perfect. It's got to be a hundred percent
6 of everything or you can just require that it be
7 a good faith effort to meet all of the seven
8 elements. And I think that's a negotiable
9 legislative issue on where you set that. But I
10 think requiring companies to buy into this and to
11 use at least good faith efforts to have a
12 program, to me that's a train that's left the
13 station. That's something that we've got to buy
14 into that. The purpose of this is to get
15 companies to engage in these types of programs,
16 and it's not unreasonable to ask them to do that.

17 To say that they have to have a
18 perfect program, I would agree with you. That
19 puts too much at risk. But to say that there
20 should be some measurable standard, some standard
21 that we can apply and say companies either have

1 or have not tried to meet this in good faith, I
2 view that as essential. I think it is only a
3 matter of time before companies will routinely
4 have to address that issue in litigation.

5 MR. GNAZZO: Can I make one comment?
6 And that is for companies -- and I'm not going to
7 tout United Technologies, but for companies that
8 started compliance programs long before the
9 Sentencing Commission came up with compliance
10 programs because we were members of the Defense
11 Industry Initiatives and established our own set
12 of guidelines and decided we were going to do
13 voluntary disclosure at that time as an
14 organization, and we have historically been
15 dealing with these compliance issues since 1986.
16 I will tell you that the two things -- that
17 realistically the two things that we've had to
18 confront over that period of time are, one, do we
19 waive attorney-client privilege when we make a
20 voluntary disclosure and, two, do we give up the
21 name of the individual who brought it to our

1 attention in a third-party lawsuit because that
2 individual is now suing us for another reason and
3 now their plaintiff's lawyer wants to get into
4 the case and wants more information with respect
5 to how individuals dealt with a particular
6 action? That's the reality of what we've had to
7 deal with.

8 The attorney-client privilege waiver,
9 we make that decision on a case-by-case basis
10 when we go in with the Justice Department, and we
11 cut whatever deal we need to cut with respect to
12 whether this is going to criminal first, whether
13 it's going to go to civil. And I'm living with
14 that decision with respect to attorney-client
15 privilege and the waiver of attorney-client
16 privilege. I don't have a problem in all
17 seriousness in making those decisions. I have a
18 monumental problem in encouraging employees to
19 come forward, and we have a program that has --

20 MR. SWENSON: You know, I think we
21 want to really kind of lay that out as an issue.

1 MR. GNAZZO: Okay.

2 MR. SWENSON: So what I'd like to do
3 is see if we can -- at least momentarily. We may
4 have time to come back to this to discuss it
5 more. But soon what we need to do is close this
6 issue and then go to you Pat and talk about this
7 very important related issue. Sean, did you have
8 anything else that you'd like to ask?

9 MR. BERRY: Just quickly.

10 MR. SWENSON: I'm sorry.

11 MR. BERRY: About the timing of how we
12 would be able to indict then. Do we need to go
13 to a judge and say that we believe that this
14 compliance program is not in good faith and,
15 therefore, we're able to indict and let a judge
16 decide whether the government brings a case or do
17 we bring a case and then litigate whether or not
18 the corporation's compliance program was in good
19 faith and risk having the case then dismissed and
20 the government is then open to a Hyde amendment
21 action?

1 MR. SWENSON: Well, what facts are you
2 assuming? You have an independent knowledge --

3 MR. BERRY: No, someone just brought
4 it into us and we think, you know what? They
5 just brought this into us because they thought we
6 were going to find out, and there really isn't a
7 good faith compliance program there so they're
8 trying to get this immunity now that's on the
9 books. And so they bring this in right before we
10 find out and, you know what, we don't buy it.

11 MR. MURPHY: You mean that the
12 disclosure is in good faith?

13 MR. BERRY: Pardon me?

14 MR. MURPHY: But that's a question of
15 how you define your program. If you look at the
16 Antitrust Division's standards, for example,
17 they've already answered your question.
18 You would not be able to make the voluntary
19 disclosure in the case where the government
20 already had enough to indict you.

21

1 MR. BERRY: Okay. I understand -

2 MR. MURPHY: I mean, that's just set
3 out right in the program.

4 MR. BERRY: I'm saying that we don't,
5 though. We do not have enough, but the company
6 fears that we will get enough or on the verge of
7 finding. And let's say wrongly. Let's say
8 they're wrong.

9 MR. MURPHY: I mean, to me that's --
10 it's relatively easy to answer that by -- I mean,
11 I think there's enough experience in companies
12 doing this type of thing that you know what
13 standards you need for a voluntary disclosure
14 program. I mean, certainly from what I've seen
15 in my experience with the Antitrust Division
16 program, it's a program that works. I don't know
17 that there are any examples of people who now
18 feel that the government got taken for a ride in
19 that type of system.

20 MR. BERRY: My question to that --

21 MR. MURPHY: That will be the first

1 point is if you answered -- you answer that
2 question by how you define it. But ultimately if
3 somebody does the disclosure and they're very
4 good and you do feel that they fooled you, you'll
5 have some basis for that. You'll have some
6 reason for believing that and you would challenge
7 that and that would go into an in camera
8 proceeding before a magistrate or a court to make
9 that determination very similar to the analysis
10 that's used for the crime fraud exception that
11 we've been dealing with for quite some time.

12 MR. BERRY: Under your idea, wouldn't
13 that -- would that decision by the magistrate or
14 the judge occur before or after indictment?

15 MR. MURPHY: Likely -- I mean, the
16 ability to indict really wouldn't be affected by
17 this. You can indict whenever you had sufficient
18 evidence, but your access to -- of course you
19 already have access to the compliance program
20 material. That's what the limited waiver means.
21 They've wasted with respect to you, so you

1 already have access. You don't have to go to a
2 judge or magistrate. You have access through the
3 voluntary disclosure. You're the only one who
4 has access.

5 MR. BERRY: I understand. I guess I'm
6 confusing your limited waiver issue versus your
7 immunity issue. I mean --

8 MR. MURPHY: Yeah, I put the two
9 together, but when I -- when the company comes in
10 that does the voluntary disclosure to you, they
11 have opened the door. They have basically said
12 that we're buying into this because you've given
13 us the assurance that you'll treat us the right
14 way because we did the voluntary. But they are
15 giving you the information. You don't have to --
16 you don't have to go to the magistrate to get
17 some waiver. They've made that waiver but only
18 with respect to you.

19 MR. BERRY: Thanks.

20 MR. SWENSON: Steve, you're welcome to
21 add anything more you'd like to.

1 MR. SOLOW: No, I'll just keep
2 listening. Thanks.

3 MR. SWENSON: Okay. Well, with that
4 we'll turn it over to Pat, who has now left the
5 room.

6 MR. MURPHY: Okay. When can I -- can
7 I drop off and do my presentation down here?

8 MR. SWENSON: I'll tell you what, Joe?
9 Can you hold on for one more question?

10 MR. MURPHY: Sure.

11 MR. SOLOW: Joe, it's Steve Solow
12 again. A lot of times in the antitrust context,
13 the major distinction drawn between that program
14 and its smooth operation and the other programs
15 like the XYZ program and the (inaudible) program
16 and the others and the reason why the HHS program
17 you see is different is because there is no way
18 for them to get these cases unless one person
19 comes forward who's in the conspiracy. One of
20 the antitrust conspirators has to come forward
21 and so there's a distinction with a difference.

1 At least that's what the Department has said in
2 the past. I just wondered -- and I know you sort
3 of addressed that in passing saying that you
4 didn't think much of that. But why is that
5 wrong?

6 MR. MURPHY: I'm sorry. I don't think
7 much of what, saying that the Antitrust program
8 that's been so extraordinarily successful that
9 the same principles don't apply elsewhere?

10 MR. SOLOW: You said in passing that
11 there were other programs that were not as good.

12 MR. MURPHY: Yes.

13 MR. SOLOW: And the Department had
14 said in the past that there were differences, and
15 I was, I think, articulating what that difference
16 was that they had said. And I wondered what --

17 MR. MURPHY: Oh, yeah. I understand.
18 Let me give you an example where I've been told
19 there's a difference that doesn't apply. That's
20 the area of bribery and overseas payments and
21 where the Criminal Fraud Division takes the

1 position that, well, this is different. And I
2 have trouble ever picturing a bribery that occurs
3 where there aren't more than two people involved.
4 It's also the case -- you are right in the
5 antitrust field that the typical disclosure is
6 another company coming in, but I think that
7 everyone involved in this area knows the more
8 common source of information on the fence is it's
9 an individual who was involved becoming ticked
10 off for some reason and disclosing what's
11 happened elsewhere.

12 And I also don't agree that the only
13 way you can break an antitrust case is by one of
14 the parties turning themselves in. As I say, you
15 can have an individual turning themselves in.
16 It's also my experience that even in these
17 conspiratorial cases, you'll have other evidence.
18 You'll have documents, that type of thing. And I
19 think in any type of offense you will have the
20 potential for at least individuals come in and
21 providing information. So I think there's an

1 important opportunity for voluntary disclosure,
2 and when you have voluntary disclosure, for
3 example, on a bribery case, as in the Baker
4 Hughes case, the company came in and voluntarily
5 told what happened which allowed the government
6 to go after other offenders, including Baker
7 Hughes employees in KPMG Indonesia. So I do not
8 see the difference and I am an antitrust lawyer.
9 I also do Foreign Corrupt Practices Act work. I
10 simply do not see a principal distinction between
11 the antitrust field and the others, and I do know
12 that the antitrust program was opposed by some
13 just as vigorously as the current opposition
14 to extending the Antitrust Division approach
15 to other divisions.

16 MR. SWENSON: Thanks, Joe. One --
17 actually, I have one last question before you go,
18 and it's -- I'm wondering whether for Chuck and
19 Sean you have anymore questions about sort of
20 something fundamental that underlies this whole
21 discussion and that is why some of these

1 compliance activities are sensitive. Why --
2 well, actually, let me put it a different way.
3 Why they can be very important for companies to
4 engage in to make their programs effective and is
5 it -- do you think -- has Joe helped you get an
6 understanding of that? Because that's sort of
7 what it relies on, I think, for all of us.

8 UNIDENTIFIED SPEAKER: Yeah,
9 definitely.

10 MR. SWENSON: Well, great, Joe. Thank
11 you.

12 MR. MURPHY: Okay. Well, I was happy
13 to participate and help in any way that I can.

14 MR. SWENSON: Okay. Take care of them
15 dingoes. What was that other animal, the
16 porcupine one that you just saw?

17 MR. MURPHY: Well, there's something
18 called an achinda (phonetic) and there's also
19 something called the forest dragon, and I have to
20 report I have actually seen a forest dragon.

21 MR. SWENSON: Okay. I wanted to get

1 that on the record. Thank you.

2 MR. MURPHY: Okay.

3 MR. SWENSON: Take care.

4 MR. MURPHY: All right. Bye now.

5 MR. SWENSON: Pat?

6 MR. GNAZZO: My name is Pat Gnazzo,
7 and by way of background, just to explain where
8 I'm coming from, I was the chief trial attorney
9 for the Department of the Navy prior to coming to
10 United Technologies Corporation and at one time
11 was Vice President for Litigation at United
12 Technologies Corporation. I'm now the company's
13 compliance and ethics officer, and I've been in
14 that position since 1993. I've been managing the
15 program. I'm the current chairman of the working
16 group for DID, the Defense Industry Initiatives,
17 and I'm a member of the Board of Directors of the
18 Ethics Officer Association.

19 United Technologies' program started
20 with DID, and in that program we made the
21 decision, along with the rest of the Defense

1 Industry Initiative companies, to establish hot
2 lines for our organization so that employees
3 could bring to the attention a management
4 wrongdoing in the area of government procurement
5 and government issues. When we did it in 1986 we
6 went one step further or maybe ten steps further
7 and we established both a written and an oral
8 program where employees could call an 800 number
9 or they could write us in a DIALOG written
10 program, and we told them they could do it
11 anonymously. They could do it with anonymity,
12 and they could do it with confidentiality. And
13 we did it through an ombuds program, not through
14 the business practice organization.

15 Today we've had over 65,000 DIALOG
16 or ombuds issues raised in the company since 1986
17 worldwide. We have 167,000 employees. We
18 operate in over 200 countries, and we have more
19 foreign nationals than we have U.S. citizens as
20 part of United Technologies Corporation's
21 employee base. That program has been in

1 existence since 1986, and I have to tell you that
2 I only get as the ethics officer four percent,
3 about four percent, of all of the 65,000
4 DIALOG or hot line calls. About four percent
5 are related to both ethics and compliance or
6 illegal activity. The rest has to do with
7 anything an employee wants to raise with respect
8 to management from I'm being harassed to the
9 traffic light outside the plant is too slow at
10 the time of shift and can you do something to
11 change it. And we respond to all of those issues
12 within a prescribed -- we try within a 14-day
13 period of time, but we investigate everything.

14 With respect to the issues that I get,
15 the four percent, those issues are thoroughly
16 investigated and reported to the audit committee
17 of the board of directors, and with respect to
18 that -- and a limited number of those issues have
19 to do with illegal activity. And, in fact, we
20 monitor some 31 categories that go to the audit
21 committee of the board. A good number of them --

1 and please understand that from a perspective of
2 a company that wants to have a strong compliance
3 program, a good number of those issues are
4 internal protection to the corporation,
5 embezzlement, accounting irregularities that
6 impact on the company and to the benefit of the
7 company to do the right thing. Not Foreign
8 Corrupt Practices Act, not fraud, not antitrust.
9 Those issues obviously are part of the 31
10 categories, but we are not only protecting our
11 corporation from doing illegal activity but
12 protecting our corporation from individuals in
13 the company that want to misuse company assets,
14 company property. So it's an effective program
15 from our perspective, not only for the prevention
16 of crime and the voluntary disclosure if so
17 necessary but also to prevent individuals from
18 doing harm to the corporation internally.

19 Our one concern obviously is
20 confidentiality of the source. We've had 65,000
21 employees bring to the attention of management

1 issues that they want to raise. Of those 65,000
2 employees, about ten percent of them do it
3 anonymously. The rest are willing to come
4 forward and give the names at least to the ombuds
5 person or the DIALOG administrator knowing that
6 we have promised confidentiality and anonymity to
7 those individuals who come forward. Those names
8 are not even given to me with respect to my
9 investigations, and we go through the ombuds or
10 DIALOG person in order to get more information.
11 They establish lines of communication many times
12 with the individual that wants anonymity. They
13 answer questions that we may ask, but we don't
14 know who the particular individual is, and then
15 we conduct the investigation and move forward
16 from there. And we've been successful in
17 protecting the 65,000 issues that have come
18 forward. Part of my job is to protect
19 individuals who claim that they are being --
20 claim that they're being impacted by coming
21 forward and using the process. That is one of my

1 obligations as the ethics officer of the company.

2 So to my issue, we would appreciate it
3 if the sentencing guidelines talked in terms of
4 confidentiality and the need for confidentiality.
5 It is very important for a corporation to be able
6 to establish good strong confidential programs
7 that employees can rely on. We've done surveys
8 in our corporation worldwide, and even though we
9 have 65,000 issues that have been raised through
10 our program, we still have 25 percent of our
11 employees who do not believe or trust that the
12 corporation will protect them or maintain their
13 confidentiality. We expect that 25 percent
14 is probably a normal number. A normal number
15 that those individuals have never had to be
16 tested were put in that kind of a difficult
17 position. However, as much as we've publicized
18 this program, as much as we've had this program
19 for 15 years, 16 years, as much as we have even
20 gone to court to protect the source, the
21 individual, by hiring separate counsel for the

1 ombudsman. In addition to U.T.C. attorneys
2 representing the corporation, we have hired a
3 separate lawyer to handle the ombuds issue to
4 explain to the court the public good versus the
5 individual right to know who the source is of
6 information that comes to the attention of the
7 company. We feel very strongly about protecting
8 that source, and anything that the Commission can
9 do to talk in terms of confidentiality, to talk
10 in terms of the need of confidentiality, would be
11 greatly appreciated with respect to keeping and
12 maintaining these programs.

13 MR. SWENSON: Pat, I assume they would
14 not help people for the commission simply --
15 well, maybe they would. Let me ask a question.
16 Would it help if the Sentencing Commission simply
17 dropped the word confidential into step five that
18 talks about, you know, internal reporting
19 processes?

20 MR. GNAZZO: That is -- at a minimum,
21 that is something that we would hope would

1 happen.

2 MR. SWENSON: Here's my concern.

3 MR. GNAZZO: At a minimum.

4 MR. SWENSON: Here's my concern. Now
5 we have government talking (inaudible). The
6 Sentencing Commission is saying it ought to be
7 confidential. The Department of Justice in
8 comments that it has submitted today, which are
9 not available -- you probably haven't seen, but
10 let me just read it to you because it's germane.
11 It's in response to a question that we put to the
12 comment --

13 MR. HOWARD: That's the question that
14 this group is dealing with?

15 MR. SWENSON: Yes, exactly.

16 MR. HOWARD: Why do you want
17 (inaudible) for what it is?

18 MR. SWENSON: Well, let me just --
19 yeah, one (inaudible). Let me just sort of skip
20 to it. Part of it is endorsing the idea that
21 other means of internal reporting "could include

1 a mechanism to confidentially," that word is
2 underlined, "report to the board of directors and
3 the board audit committee where appropriate
4 without fear of retaliation." Sawbones-Oxley in
5 talking about the need for internal reporting
6 processes that the audit committee has to put in
7 place uses the word confidential. Now perhaps
8 the Sentencing Commission can do the same thing.
9 The reality is that all of these statutes,
10 pronouncements require, in essence, to have a
11 bona fide program, but you're still in the same
12 litigation boat of who wants to go forward.
13 You have no protection whatsoever apart from your
14 ability so far, and you're probably giving the
15 company to go in and argue and defend an ombuds
16 privilege to protect the confidentiality of that
17 source.

18 So I guess my fear is it's put into --
19 put in as a requirement, but the litigation
20 environment hasn't changed. So companies are
21 promising something they generally can't relay.

1 MR. GNAZZO: From a litigation
2 perspective, I think that we pretty much
3 insulated ourselves as best we possibly can. And
4 understand our program is a separate program. We
5 have a separate ombuds person and we have
6 separate ethics officers and we have maintained
7 over and over again that those who investigate
8 our files are discoverable, for the most part,
9 unless there's a attorney-client privilege that
10 even sues. And we use attorney-client privilege
11 sparingly because we don't want to be in a
12 position of constantly putting every
13 investigation under an attorney-client privilege
14 and misusing the process.

15 So my files are discoverable. The
16 files of the HR department are discoverable, and
17 in many instances the files of every -- the
18 environmental department or any of the other
19 departments that take action or take official
20 action are discoverable. We've argued that the
21 files of the ombudsmen shouldn't be discoverable

1 on the grounds that they are neutral. They are
2 passed through. They are not an individual that
3 takes any -- does any investigation, does not do
4 any reviews. All they do is pass information
5 from the employee to the company, the company
6 back to the employee, but in effect take no
7 action, act as a neutral. Our argument is that
8 it would hold stronger weight if we could point
9 to the use of confidentiality or the expectation
10 of confidentiality, not only internally but
11 externally in the statements that are made by the
12 Sentencing Commission.

13 MR. SWENSON: Let's imagine a company
14 other than UTC which does not have an ombuds
15 program because you already have had some
16 success. How many cases have you brought
17 defending the privilege?

18 MR. GNAZZO: Five or six and one in
19 England, and, actually, we were successful in
20 England too.

21 MR. SWENSON: So you were successful

1 in half-a-dozen cases?

2 MR. GNAZZO: Yes.

3 MR. SWENSON: Companies that don't
4 have an ombuds program are not in the position to
5 make that argument and may not have as good of
6 lawyers. I don't know. They're not in a
7 position to --

8 MR. GNAZZO: That was a compliment to
9 you, Chuck.

10 MR. SWENSON: -- to make the argument
11 that you're making because they don't have an
12 ombuds program, but in the sense they may be in
13 the same position, which is they want to tell
14 their employees that we know this can be a hard
15 thing to do. We want you to feel comfortable
16 coming forward. We'll protect your identity.
17 They don't have your six cases --

18 MR. GNAZZO: And -

19 MR. SWENSON: So my feeling is we say
20 your program must allow for confidential
21 reporting, but there is simply no way that a

1 company can make that promise and mean it in the
2 current litigation environment.

3 MR. GNAZZO: I totally agree. Take
4 United Technologies out of the equation and talk
5 in terms of any other company that wants to have
6 an 800 number or a hot line. What we understand
7 to be the case because of our experience --
8 because of our 65,000 employees that have used
9 this from time to time, what we have learned
10 through our experience is it is extremely
11 important for a company to go to every measure it
12 possibly can to protect the individual when they
13 come forward in the use of the investigation and
14 how we do the investigation, how we even tell
15 management what we found, and who was the
16 individual that brought it to our attention. All
17 I'm saying is forget the ombuds privilege, forget
18 the ombuds person. What I'm saying is companies
19 should understand the need for confidentiality if
20 they want employees to come forward.

21 Publicizing confidentiality when they

1 ask and tell employees that it's their duty and
2 obligation to come forward should mean something
3 more than window dressing. It should mean
4 something to management. It should mean
5 something to the commission. It should mean
6 something to the Justice Department. It should
7 mean something to even judges in saying that for
8 the public good wherever you can strengthen the
9 ability of employees to feel comfortable about
10 coming forward without fear of retribution, you
11 should do that. And this is a public obligation
12 on the part of the Sentencing Commission, public
13 corporations, and the Justice Department and any
14 other regulatory body is to want individuals to
15 come forward. And whatever we can do to talk in
16 terms of confidentiality, encouraging management
17 to have confidential programs, encouraging judges
18 to understand and respect confidential programs,
19 and having lawyers on both sides understand and
20 respect the needs for confidential programs would
21 be helpful.

1 MR. HOWARD: Were they criminal cases?

2 MR. GNAZZO: No, no, they were all --
3 they were all third-party lawsuits. They were
4 all individuals who actually used the program and
5 then for one reason or another were fired for --
6 and it had nothing to do with illegal or business
7 practice type issues. They used the program.
8 Later on they were fired for whatever reason and
9 wanted to then bring in the ombuds structure, and
10 we were able to explain that in that process that
11 person was a neutral. Any information that that
12 person had was developed as a neutral and that
13 the files of -- the company files were
14 discoverable, so they were all third party.

15 And that's -- and that's -- obviously
16 in having that kind of a program what I went back
17 to say originally is we built a road map for
18 private litigators. We built a road map that
19 said that we have this program and we have 65,000
20 cases where employees brought certain things to
21 our attention. Now they may be cases of

1 harassment. They may be cases of parking
2 violations. They may be any number of cases, but
3 we built a road map. We would like some measure
4 of protection wherever we can for those
5 individuals to come forward.

6 MR. HOWARD: Well, what would you
7 suggest then further on for the criminal
8 situation? Do you keep relying like we do now
9 with -- in U.S. Attorneys' work, a lot of
10 confidential informants are -- virtually all the
11 narcotics cases involve, as you know,
12 confidential informants. You keep it
13 confidential. Some cases go onto trial without
14 them, as you no doubt well know.

15 MR. GNAZZO: I would venture to say
16 that in 95 percent of the cases that we would
17 ever get involved in from a criminal aspect that
18 the individual would be known both to the company
19 and, therefore, would have to be given up to the
20 Justice Department in dealing with that
21 particular activity. There are one or two

1 occasions where we don't even know who the
2 individual is. So the question is then, are you
3 going to violate that privilege? If I give you
4 everything that I know as a company, if I give
5 you all my investigative reports, and if I'm even
6 willing to give it my attorney-client privilege,
7 do I have to also give up my ombuds person who
8 has sworn that he would never reveal the source
9 or the name? And that's the concern that we will
10 always have. We've never had to do that. We've
11 never had to be in that position. We train our
12 ombudsmen to bring people into the light of day
13 for the most part. We train our people to want
14 to come forward and give us their names. To that
15 extent, if we have the name we will give it to
16 you if we're asked to do that.

17 MR. SWENSON: Pat, hypothetically if
18 you ever find yourself in that position where if
19 somebody has gone to the ombuds person and
20 they've committed a crime, you eventually sort of
21 -- you've become -- you do an investigation. You

1 find that this actually occurred. What would you
2 do in that situation?

3 MR. GNAZZO: In that particular
4 instance, the ombudsman is never going to tell me
5 that that individual was the person that came
6 forward. But I'm going to name that individual
7 as one of the bad actors.

8 MR. SWENSON: That you found
9 independently?

10 MR. GNAZZO: In the investigation that
11 I found independently and turn that over to the
12 government.

13 MR. GOLDSMITH: I have a question.
14 This reflects on how long I've been in law
15 enforcement. The informant's privilege, it's not
16 absolute, is it?

17 MR. LARSON: No.

18 MR. BERRY: No, there's a balancing --

19 MR. GOLDSMITH: There's a balancing of
20 sorts? The court can require a disclosure and
21 then drops the case as long as it's not --

1 MR. BERRY: Sure, sure.

2 MR. LARSON: Now we'd have to evaluate
3 it.

4 MR. GOLDSMITH: Right. In terms of --

5 MR. LARSON: That's the only
6 eyewitness you had and it's extremely important,
7 but it's not uncommon, as most of you know, to
8 not have to give up the confidential informant.
9 And in many cases --

10 MR. GOLDSMITH: The reason I ask the
11 question is because my recollection being
12 accurate that the informant's privilege is one
13 that involves the balancing of sorts. It's hard
14 for me to imagine a circumstance, at least
15 judicially, in which a privilege would be
16 conferred upon employees that would be anything
17 better than what the informant would enjoy,
18 which, again, speaks to the need for some
19 legislative resolution of this matter.

20 MR. GNAZZO: What we're trying to
21 raise, though, is we'd like to make sure that

1 everybody understands where the scale should be
2 with respect to confidentiality. And the more we
3 can talk about it, the more we can try to
4 guarantee it, the more we can try to protect it.
5 From all sides the better off we are in getting
6 the information the individuals need. I know
7 that we'll never protect every instance, but we
8 want to make sure that we still have programs in
9 place that people feel comfortable about coming
10 forward, and if there's cooperation both from the
11 Sentencing Commission in talking in terms of the
12 need for confidentiality and other parties
13 understanding the need for confidentiality for
14 the public good, the value then becomes better
15 for us in talking to management about maintaining
16 those strong programs.

17 I'll make one final point because I
18 know you have to move on. And in addition to
19 obviously our interest in source protection, one
20 plea to the Commission and it's a constant plea.
21 For companies that have been managing these

1 programs for long periods of time, we obviously
2 fight budgets like everyone else for compliance
3 programs and for strong compliance programs. The
4 need for metrics, the need for data from U.S.
5 Attorneys in negotiating settlements that take
6 into consideration compliance programs in either
7 the lessening or the increase of penalties based
8 on this compliance programs would be very helpful
9 for any corporation that wants to look at --
10 sometimes we forget the fact that most
11 corporations are run by metrics and they look at
12 numbers and they look at cost benefit analysis
13 for just about everything. And the value in
14 being able to say look there have been this many
15 cases that occurred, and the Justice Department
16 in their settlements have taken into
17 consideration the Sentencing Commission
18 guidelines and have either reduced penalties or
19 increased penalties based on the fact that
20 companies didn't have a program or did have a
21 program. It's as simple as that. Will they take

1 it into consideration, did they have a program,
2 and was the penalty increased or reduced based on
3 the fact that they didn't have a program or did
4 have a program would be very helpful for anybody
5 trying to establish or keep or maintain a
6 compliance ethics program in their corporation.

7 MR. SWENSON: Just a point of
8 clarification, the Sentencing Commission has data
9 on what happens in real cases where there has
10 been a conviction and a sentence imposed.

11 MR. GNAZZO: But that's because --
12 that's because there is a case.

13 MR. SWENSON: Right.

14 MR. GNAZZO: But in the settlements,
15 we have no information.

16 MR. SWENSON: Exactly, and we -- I
17 think this is an important point. It kind of
18 comes out of this morning's discussion. Bill
19 Lytton kind of touched on that briefly. It's
20 sort of in his article. The concern that the
21 Department in its own charging policy says that

1 compliance is a consideration, but it's sometimes
2 hard to tease out of the different statements
3 about how to handle the case if that really was a
4 consideration and how the consideration came into
5 play.

6 UNIDENTIFIED SPEAKER: Even if it is
7 captured, it's only the tip of the iceberg.

8 MR. SWENSON: Right.

9 MR. LARSON: Well, we did -- I chair
10 that white collar crime sub-committee, and I've
11 invited Win to come to the next meeting in
12 January. Maybe we can formulate an action item
13 or a point to narrow that down and then give
14 support to the Department of conducting some kind
15 of survey to get an answer for you. It seems
16 like it's quite --

17 MR. GNAZZO: I don't need to know
18 names. I don't want to know amount.

19 MR. LARSON: No, no. We know that.

20 MR. GNAZZO: All I need to know is
21 it's been applied and there's been an advantage

1 or a disadvantage based on the fact that it
2 exists or didn't exist.

3 MR. LARSON: Yes, and if Win can help
4 us formulate the issue and come in January,
5 that's not too far off, that would be helpful
6 because we want to see people have good effective
7 prevention. Just like a drug situation or
8 anything else, it's all about prevention.

9 MR. SWENSON: Thank you, and we will
10 -- so we have an invitation to pursue that. It's
11 much appreciated.

12 I guess the only other -- before we
13 leave this topic, the only other question I have
14 is sort of like the question I asked at the close
15 of our last topic, which is, you know, have we
16 made the case here? Is it understood why
17 employees are often reluctant to come forward and
18 how a promise of confidentiality can be very
19 helpful?

20 MR. GNAZZO: I think the case -- if I
21 could just make one final point. The case needs

1 to be made that a corporation is not an identity
2 that doesn't have many faces. Individuals
3 management, individuals come and go. With
4 167,000 employees, attitudes change from time to
5 time. Support for various things are going to
6 change from time to ti Institutionalizing
7 words like confidentiality and institutionalizing
8 programs becomes the value in being able to route
9 out these types of issues.

10 So today I can tell you that a
11 corporation has all the right ingredients to want
12 to do the right thing, but there are faces that
13 may come into a corporation at any one point in
14 time that are going to prevent that. Having
15 these words and encouraging confidentiality and
16 protecting confidentiality is something that
17 these faces will not be able to destroy if we
18 develop these kind of programs with
19 confidentiality and the support of government.

20 MR. SWENSON: I guess I'll just throw
21 into the record, there have been a couple of

1 studies done -- boy, several. I know The Ethics
2 Resource Center has done a number over the years.
3 KPMG did one a few years ago which tends to
4 support what you found in your own company, which
5 is that there is -- even with a company's best
6 efforts, there's always sort of a residual number
7 of people with fairly significant -- and you said
8 25 percent still didn't quite believe you meant
9 confidential when you said it. I think there are
10 even higher numbers on average in many companies
11 of people who think they will be retaliated
12 against if they come forward, and it isn't a
13 function of the company being a bad company.
14 It's that there is a certain amount of fear
15 associated with coming forward period regardless
16 of best efforts. What you're really saying here
17 is that the best effort to encourage people to
18 come forward would have to include some promise
19 of confidentiality.

20 MR. GNAZZO: Well, as you said, when
21 were you part of the KPMG study that talked in

1 terms of fear of retaliation it was something
2 along the 60 or 70 percent range from a lot of
3 individuals who were just asked these questions
4 who worked for small companies or large
5 companies. There was a large proportion of the
6 population that doesn't trust management. It is
7 not going to retaliate if people come forward.
8 No matter how much we talk about it, no matter
9 how much we emphasize it, and no matter how much
10 we prove that we have not done something to
11 impact, there is going to be a certain amount of
12 skepticism. And any support for confidentiality
13 would be helpful.

14 MR. BERRY: And I think the United
15 States -- we wouldn't necessarily disagree with
16 that, but you also understand that there are some
17 instances where we can't promise confidentiality?
18 Ultimately the testimony may be needed. The name
19 may need to be revealed. While we agree with you
20 that confidentiality is important to have people
21 step forward to have your programs work, it's

1 just not something that from our position we can
2 say and, therefore, it should be guaranteed.

3 MR. GNAZZO: I think if the decision
4 is based on an absolute need, fine. If the
5 decision is based on just trying to beat the
6 company over the head, that's a different story.
7 The only way we're going to ever separate that
8 out is having policy statements that talk in
9 terms of the value of confidential programs.
10 Then we at least have set a standard that
11 everyone is going to have to deviate from on
12 those exceptions.

13 MR. LARSON: Now is there (inaudible)
14 had lots and lots of calls coming in, but it has
15 significantly prevented fraud and wasting fraud
16 and abuse.

17 MR. GNAZZO: Absolutely.

18 MR. HOWARD: If I could just jump in
19 here a little bit. As Pat said, I do know
20 something about this, but one of the -- and I
21 agree with everything that Pat has said, but one

1 of the things that makes this work is that you've
2 kind of separated an information process and a
3 counseling process for employees from the couple.
4 The ombudsmen is independent, neutral,
5 confidential, doesn't investigate, doesn't make
6 any -- doesn't make policy, doesn't implement
7 anything and so the function there really is one
8 of filtering information, assisting the
9 employees, giving them the comfort to come
10 forward.

11 To the extent that the company -- that
12 the issues come forward, maybe they come forward
13 in a way that the company now knows that there's
14 an issue but may not know who's doing. What Pat
15 has described is that the company then does all
16 of its work through the compliance the way it
17 always has done, and that's -- that's what
18 they're willing to share and provide. But at the
19 ombuds confidential protection since it's
20 nonoperational. It doesn't -- it's not part of
21 management. The company has kind of separated

1 those two functions. And at least in that case
2 and some others, it has worked fairly well
3 simultaneously allowing people to feel
4 comfortable coming forward handing off issues
5 that allow the company to then take responsible
6 action with them.

7 And (inaudible) his work in some ways,
8 but by saying confidentiality is important, you
9 give the company that much more leverage to
10 essentially justify and support its promise of
11 confidentiality.

12 MR. GNAZZO: But if I could just give
13 you a quick example of the way something like
14 this would operate, an individual is an
15 administrative assistant to a high-level person
16 in a corporation and is aware of something that
17 that high-level person is doing and is the only
18 person that is aware. So you've got two people
19 that are committing. One person is committing
20 the act and the other person is either an
21 unwilling participant or a knowing individual,

1 and that individual goes to the ombuds person.
2 The ombuds person is trained to have that person
3 come back, call back in two weeks, call back in
4 three weeks, comes to the business practice
5 officer and says, "What are you going to do to
6 help this person if they're able to tell you
7 what's going on." And I may go in and talk to
8 this individual anonymously over the phone when
9 they call back and give them some kind of comfort
10 that if they tell me that it's X division of the
11 company and they tell me it's a vice president of
12 that division and if they give me the
13 circumstances that might have occurred, I can
14 order an audit of every vice president's expense
15 report, for example, for a six-month period of
16 time in that particular division. And I
17 guarantee you we have uncovered things based on
18 that, and the individual has then been fired and
19 the person who brought it to our attention I've
20 never known their name. I've never needed to
21 know their name, and I've never even gone back to

1 them to say, hey, you did a nice job. But they
2 know what happened and they know how it happened
3 and they know that their name never came forward.

4 We will go to those extremes to
5 protect that individual's anonymity. All we
6 would want to do is have people understand that
7 if you do have a strong program, if you care
8 about your program, if you care about protecting
9 your corporation in the public entity, then we
10 need support wherever we can get it.
11 Understanding that there are exceptions to every
12 rule.

13 MR. LARSON: Say somebody calls in and
14 their conscience finally bothers them. They've
15 been a party to an ongoing conspiracy. Then the
16 question that comes then -- it's a hard question.
17 Do we charge them?

18 MR. GNAZZO: Our policy clearly tells
19 them that if they are a participant to an ongoing
20 activity and they're involved and they've been
21 involved, they're not immune. We tell them in

1 advance that they are not immune, that they don't
2 get -- they don't get immunity just by coming
3 forward.

4 MR. HOROWITZ: That was actually what
5 my question was going to be. What do you tell
6 them about confidentiality, immunity, and
7 retaliation?

8 MR. GNAZZO: We tell them that if they
9 had been a participant to the activity, they are
10 not immune. They still have an obligation to
11 come forward, but we're really concerned not so
12 much with the individual who committed the act or
13 the person who participated in the acts, but the
14 individual on the sidelines who's watching the
15 act occur, has not been participating in the act,
16 knows that it's happening, has an obligation to
17 come forward because we tell them that they have
18 an obligation to come forward. Those are the
19 individuals that we need to protect. It's not
20 the individual who is participating because that
21 individual is going to get caught up in the

1 investigation. That individual is going to be
2 terminated, and if it's a criminal activity, that
3 individual is going to be made known to the
4 Justice Department, along with everyone else that
5 participated. We're not going to be able to
6 avoid that. And that's not that we're trying to
7 avoid. We're trying to avoid the individual
8 who's on the sidelines and fearful of coming
9 forward.

10 MR. HOROWITZ: And I guess my question
11 is I know what in my former life we had to do
12 when you had someone coming off the street who
13 was a witness and wanted to report something.
14 You would tell them to go to whatever means
15 necessary to protect their identity. Often times
16 you would set up several layers between them and
17 the sting you ultimately did so that there would
18 be several layers of protection, but you also
19 always tell them that you can't make a hundred
20 percent guarantee. And that's what I'm trying to
21 get from you is --

1 MR. GNAZZO: Right, but you need to
2 understand the context for a corporation opposed
3 to a Justice Department in giving immunity. In a
4 context of a corporation, I have a bad actor
5 who's going to be here next year and the year
6 after that and the year after that. If I turn
7 around and say I'm going to protect that bad
8 actor because that actor was a participant but
9 then came forward halfway through the activity as
10 one bad actor along with ten others, I've still
11 got that bad actor in my system. What does that
12 say about that piece of the compliance -- the
13 sentencing guidelines that says that I still have
14 somebody in a position of authority when I
15 knowingly know that that individual was doing
16 something corrupt. So, I mean, I can't protect
17 that individual because I'm not going to want
18 that bad actor to stay in the company for periods
19 of time beyond that.

20 MR. HOROWITZ: But I guess I want to
21 go beyond that, beyond the immunity issue, to the

1 innocent person on the sidelines. What kind of
2 representations does a company like yours that
3 has this program in place -- what are you able to
4 tell them? Is there some comfort level? That's
5 what I'm wondering.

6 MR. GNAZZO: That's something you need
7 -- that's something you need -- we tell -- we
8 tell employees that if they go to the ombuds
9 DIALOG process, we will guarantee immunity. We
10 will guarantee confidentiality. Now we tell them
11 if they come to me, I can't guarantee
12 confidentiality. I'll try to do the
13 investigation as best as I possibly can without
14 naming them, but if they go to the ombudsman we
15 will guarantee it. Now how do I guarantee it? I
16 guarantee that the ombudsmen will never be shaken
17 down by anybody in the company for that
18 information, and I will guarantee it by hiring an
19 outside counsel to protect the ombuds and the
20 ombud's information in any litigation. That's
21 the extent of my guarantee, and we tell our

1 employees that that's what we will do. So no
2 management person can ask the ombuds - or they
3 can ask, but they're never going to get the
4 answer because the ombuds people and the DIALOG
5 administrator -- and I have our ombuds person
6 here, MR. WRATNEY. Do you feel protected by me?

7 MR. WRATNEY: Absolutely.

8 MR. GNAZZO: Feel free to speak. But
9 my position -- my position is one that says I am
10 supposed to protect the information that goes to
11 the ombudsman, and I report to the audit
12 committee, the board of directors, and they know
13 that that's my function. So for a publicly-held
14 company, my obligation is to protect that -- the
15 ombuds and the DIALOG people. So far we've
16 been able to do that.

17 MR. HOROWITZ: And I assume that's
18 where the whistleblower protection comes in?
19 Confidentiality leads to protection.

20 MR. GNAZZO: Yes.

21 MR. SWENSON: Anything else before we

1 move on? We can come back.

2 MR. LARSON: Just an anecdote to prove
3 MR. Gnazzo's point that a lot of employees worry
4 about this. My cab driver Tuesday night in the
5 rain had just lost his job. Actually, the
6 corporation has an office in Cedar Rapids, in
7 fact, and so he says, "But I was a whistleblower
8 and that's why they let me go." Although they
9 had a big layoff and so I said, "Sarbanes-Oxley.
10 Tell your lawyer Sarbanes-Oxley." When I got out
11 of the cab -- and he was excited and almost drove
12 off with my suitcase.

13 MR. SWENSON: Ken?

14 MR. JOHNSON: Yes. We can go from
15 macro to micro. I am an independent consultant,
16 and I'm representing a group called the Coalition
17 for Ethics and Compliance Initiatives. A lot of
18 folks in this room have been involved in it.
19 It's a very loose organization. It will have a
20 web site next week, I think. We have an interest
21 in having effective ethics and compliance

1 programs. And the early, early topic that we hit
2 on was this confidentiality issue. What I had to
3 contribute here -- because I have nowhere near
4 the experience that Pat and George have in terms
5 of the practice, but I do have -- I can tell you
6 what some of the objections we've run across in
7 the field are.

8 George and I made a point of going and
9 talking to as many people as possible to find out
10 what the really bona fides were for this issue,
11 including talking to voluntary disclosure program
12 people, IG for DOG -- DOJ - or DOG -- DOD and
13 organizations. We have not quite gotten the
14 confidence to go with the trial lawyers yet, but
15 I'll do this down the line. But what I want to
16 do is bring a couple of things together here and
17 say what -- I've made a note to myself. What
18 we're hearing a lot is systemic ignorance. You
19 heard it from Joe. You heard it a couple ways.
20 I don't want to know. Don't tell me who you are
21 or whatever else for all sorts of very good

1 policy tactical reasons. Most of it goes
2 ultimately down to you gentlemen, that is that
3 they will demand this information that will hurt.

4 Someone used this comment of, "No good
5 deed goes unpunished." When I was a lieutenant
6 in the Marine Corps in Vietnam, an old gunney
7 said, "I don't mind dying, but I don't want to
8 die stupid." And so you see a lot of this is the
9 fear. It's that, well, look, I'm going to go and
10 do the right thing and then I'm going to get
11 popped and punished and people will say why on
12 earth did you do that because you could have kept
13 quiet. So what I think we're looking for in many
14 ways is not the companies doing the right things
15 but the context of which the Justice Department
16 and the voluntary disclosure programs are apart
17 that says, look, we really do want you to come
18 forward and we'll do everything we can to make it
19 so you don't look stupid when you do the right
20 thing. Part of this has to do with this promise
21 of confidentiality. It has to do with being able

1 to make an enforceable promise that I promise you
2 that if you come give me information I will do
3 the right thing with it and you won't be
4 penalized for all sorts of reasons.

5 We talk about management retaliation
6 that this -- the alleged -- the research also
7 indicates they're afraid of peers, let alone
8 management. So how do we promise that? So one
9 thing that I would ask -- and I've got some real
10 wrap up recommendations or suggestions at the
11 end, but I think that in terms of commentary we
12 need to look at the importance of the culture of
13 the organization and the context in which the
14 organization does business to decide if it's
15 designed an effective program.

16 If you have a culture where everyone
17 will speak up, then you don't need all these
18 confidential mechanisms except to meet the
19 requirements. If they don't, then you've got to
20 find mechanisms to get them to speak up. In many
21 ways that's a promise that says, look, you can

1 call and we'll do it anonymously, which is fine,
2 but you don't get all the information you want if
3 you do it anonymously. So the next step then is
4 confidentiality.

5 In my practice I've evaluated ethics
6 programs for companies that are in trouble with a
7 number of agencies, including the Air Force
8 voluntary disclosure program. When I go in and
9 do interviews in focus groups, I have to sit them
10 down and say, now, your organization has promised
11 confidentiality. Oh, okay, good. So you can
12 talk to me. However, I have to tell you that I
13 have to give a whole long litany of all the
14 things that could go wrong. By the time I do
15 that, the list over what could go wrong far
16 outweighs the promise of confidentiality. And I
17 have no idea what knowledge I didn't get that
18 wasn't passed in my report to the Air Force that
19 used them to make a decision regarding their
20 program. And so it's an -- it's a knowledge
21 issue, and we need to do what we can to do that.

1 That, of course, is where these privileges come
2 in.

3 There's a strong bias against
4 privilege. There's no question about that. We
5 want all this information to come forward. But,
6 on the other hand, there are any number of areas,
7 privileges, like relationships that are
8 protected. There is the Wigmore test and all
9 this sort of thing. But there's also things like
10 the repairing -- you know, the damage remedial
11 repair sort of thing where the best proof going
12 is that somebody repaired the step that was
13 broken and we say, no, you can't use that. Well,
14 why? Because we'd rather get it repaired than
15 have that little bit of evidence that makes the
16 prosecution easier.

17 So I have many more comments to make,
18 but I think we've touched on it. The key to what
19 I think here is that -- and I was a litigator
20 many, many years ago in a former life, and I
21 would have to say that if I were making my living

1 in the plaintiff's bar, I would rather give up
2 not knowing who came forward with the information
3 that led to the organization to report the
4 misconduct that I now found about and I can sue
5 on than to keep it such that I desperately want
6 to know who brought that forward and then they
7 don't. So I never even knew it happened. So it
8 seems to be on balance from a public policy
9 perspective; we're much better served if we can
10 say, look, just this little bit of information,
11 who was it that came forward and reported the
12 misconduct. We'll -- it's off the table. We
13 won't even worry about that. We'd rather
14 encourage people to come forward. And I think
15 that can be an absolute privilege. I think as a
16 prosecutor that I was one time. I think I -- and
17 I'm not any longer, but I think I probably would
18 sign onto that.

19 Now what it requires, of course, is
20 good faith on the part of the company that will
21 actually do things with the information. And in

1 that sense, that's where you get into having an
2 effective program of which this confidentiality
3 is but a part - a contextual thing that makes it
4 possible. And if they don't have an effective
5 program, then there's no privilege. The only
6 thing that Pat is concerned about is not so much
7 keeping information down. He's concerned about
8 having his program be effective and they won't
9 come forward. So if he didn't have an effective
10 program, then he's lost nothing. So the idea is
11 have an effective program of which this
12 contextual thing helps, and let public policy
13 say, fine, just like that broken step, we'll let
14 that go. You got to do it in good faith. They
15 come forward and make the information. We won't
16 inquire as to who it was that brought it forward.

17 Now what happens if you can't prove
18 it? I mean, let's take the acid cat test and
19 say, you know, maybe we could have proved it if
20 we had just known that little bit of information.
21 You know, we've learned a huge amount. First

1 off, somebody in the system, because it came
2 confidentially, knows that it happened and knows
3 who brought it forward. Now you can't retaliate
4 against them, but that doesn't mean that you
5 can't fix the problem. It also doesn't mean that
6 if you find out that, my God, you can't -- you
7 know this happened because U.T.C., to give an
8 example, Pat's closest reported it but you can't
9 prove it criminally, then you know that you've
10 got major problems in terms of all the systems
11 and everything. Even if assuming you've got an
12 effective program. But assuming you don't, you
13 now know that your standards are not -- let's go
14 through them. You know your standards are not
15 adequate, right? You know your auditing
16 monitoring is not adequate. You know that the
17 training for this kind of thing is not adequate.
18 So even from a social policy there, you've
19 learned so much more.

20 Now I grant you it could be a
21 horrendously horrible criminal case and this kind

1 of thing and it would make it more difficult.
2 But on balance, I think that to preserve this
3 ability to prosecute -- and I'm trying to say
4 easy and that's really not it. The ability to
5 have that little bit of information that actually
6 kicks this notion forward, I think is -- I think
7 is -- I think it's short-sided. I think it
8 really is the case of saying, look, if you can
9 show you have a bona fide company and we now know
10 there's -- there's a tremendous book on
11 whistleblowers by Mark Alfred at the University
12 of Maryland that is a horrifying story. It's
13 just -- he talks about the exposure -- the
14 experience of whistleblowers as being like being
15 on another planet. They're so isolated
16 (inaudible). I think we can support them, those
17 individuals and organizations, by saying, look,
18 we will let people come forward with a promise of
19 confidentiality provided the organization
20 demonstrates it does -- it uses it well. Society
21 will be better preserved by preventing or earlier

1 curing these problems than they will be in the
2 punishment. And what happens is with the
3 knowledge that they voluntarily brought the
4 information forward but you can't make the case
5 probably means they don't have an effective
6 program, and it also means that there are major
7 things that have to be changed. There's a lot of
8 benefit to that, both from a management
9 perspective and, I think, from a public policy
10 perspective.

11 I think what I would suggest in terms
12 of approaches for the advice we give to the
13 Commission is that in your commentary you do make
14 an expressed note that these programs are
15 dependent upon the culture of the organization
16 and its context of which a privilege is a key
17 aspect because if there is a privilege then one
18 can promise confidentiality. If not, then they
19 can't, which means their whole -- the number
20 five, step five, their auditing and monitoring
21 processes has to be more auditing and monitoring

1 than the confidential reporting. So it's a fact
2 that needs to be taken into account just like the
3 size of the organization.

4 I think it would be very helpful to
5 Pat's note that the Commission would note in
6 commentary that there are salutary effects of
7 privilege, that some anecdotal experience or
8 research does indicate that a privilege would
9 help. I think -- I think this is probably going
10 too far, but it did seem to me that some of
11 legislation -- the authorizing legislation
12 talks about outreach. Perhaps even a call for
13 judicial legislative privilege would be
14 appropriate or at least further study. It
15 certainly is the case -- and George may remember
16 this is that we met with some of the IGs with the
17 DOD. I think Dick Bednar set us up to talk to them.
18 One of them said, well, how do we even know that
19 more people will speak up if there is a promise
20 of confidentiality. I think that's an area that
21 needs to be researched. I think it's something

1 that the Ethics Resource Center or what somebody ought
2 to do is find out would a promise of
3 confidentiality really bring more people forward.

4 MR. SWENSON: Ken, is that -- just to
5 interrupt for a second.

6 MR. JOHNSON: Yes, go ahead.

7 MR. SWENSON: Is that your position
8 that before we arrive at the right policy
9 that there ought to be more research on that
10 question? I mean, you're putting it forward and
11 certainly had argued very strenuously in favor of
12 it. But this is not something we need to
13 speculate about, but, in fact, a promise of
14 confidentiality does encourage people to come
15 forward. Is it your position that we really
16 don't know?

17 MR. JOHNSON: I think it would be very
18 helpful particularly to people that really have
19 the obligation of prosecuting cases to see that
20 there's research indicating yes, there is that --
21 it's a tough thing to do. Now there's a lot of

1 -- intuitively it makes sense, and I think that
2 we're certainly getting anecdotal experience and
3 probably we could pull together stuff to look at.
4 I'm just not aware of any studies that we could
5 point to that says yes, you have that --

6 MR. SWENSON: It's sort of inferential
7 from some of the surveys that have (inaudible)?

8 MR. GOLDSMITH: In terms of studies,
9 during my experience with the Commission our
10 staff was just terrific in engaging all kinds of
11 sophisticated research and issued so-called staff
12 studied reports on their good issues. This might
13 be an appropriate one for the staff to examine in
14 detail. They could interview practitioners,
15 people from the Justice Department, various
16 principals of companies, employees, et cetera.
17 The Commission has the resources to do that. And
18 what I like about that is it would then produce a
19 report that, in turn, could be cited in the
20 courts to make the kind of case that you're
21 trying to make and document the need for this in

1 the public good argument for all of that.

2 Short of a staff study -- which I
3 think is eminently doable, and I really would
4 hope that the Commission could do that. If the
5 Commission conducts a hearing in which they
6 receive testimony comparable to what they heard
7 today and that testimony, in turn, is published,
8 then that would generate hearings that could be
9 cited during the course of court proceedings
10 that, I think, would also be helpful.

11 MR. HOROWITZ: In terms of the
12 self-evaluative privilege and what it would mean,
13 confidentiality is one aspect of it to encourage
14 people to report. We had talked earlier, and I'm
15 just going back to the use immunity discussion
16 which flows out (inaudible) to this notion
17 creating a privilege. And my question in that
18 area is, are you familiar with any studies or any
19 surveys that show that having such immunity --
20 well, let me back up.

21 In -- and maybe this first question is

1 for Pat, which is that a public or regulated
2 company really has an obligation to do the
3 evaluation, privilege or no privilege. You've
4 got to do it and you've got to self-disclose if
5 you find something. So we're putting -- we
6 probably should put, unless anyone disagrees,
7 regulated companies to the side because they have
8 a whole different set of issues that they have to
9 deal with. They have to go forward if they think
10 there was wrongdoing in the company. So now
11 we're talking about unregulated companies. And
12 is there any evidence to suggest that those
13 companies are when they -- when high level
14 officials or even ethics or compliance officers
15 who aren't sufficiently (inaudible) learn that
16 there may have been wrongdoing, that they are
17 making a decision not to evaluate or not to
18 investigate because of the consequences that come
19 forward with that? Because that to me -- it
20 seems to me to be an important question for
21 people who want to see an evaluative privilege or

1 actually more (inaudible) an immunity provision
2 put in place.

3 MR. JOHNSON: One thing that strikes
4 me, and I guess I wish I had asked Joe this
5 question, now is if you look at a self-evaluative
6 privilege because an incidence has arisen is kind
7 of one issue. What I'm in favor of and in
8 earlier bid I submitted, I recommend an eighth
9 step to the sentencing guidelines. I think the
10 guidelines are wonderful pretty much as written
11 with some minor tweaking. I would add an eighth
12 one that says that you need to demonstrate that
13 you've evaluated your program for effectiveness
14 on a regular basis. It's very similar to what
15 Lynn Sharp Paine said that in the corporate
16 America it's unusual that one has programs that
17 one doesn't evaluate to see if it's effective and
18 that is not to be found in those seven steps, as
19 I think someone else said.

20 If you added that into it, it's not
21 that that would be a complete answer to you but

1 it would be close because it wouldn't be an
2 episodic self-evaluation. It would be that this
3 is what we regularly do and if we don't regularly
4 determine we have an effective program with
5 metrics and criteria, then we don't have an
6 effective program. And so I think that's the
7 distinction between an episodic self-evaluation,
8 which I would be suspicious of frankly, and one
9 that's a regular basis of doing business, which I
10 would support wholeheartedly.

11 MR. SWENSON: I think we do have on
12 the record from Lynn -- I'd have to go back and
13 check. But I think she voiced the view that she
14 thinks there is not very much evaluation going
15 on. You're saying --

16 MR. JOHNSON: Yeah, it's very much --

17 UNIDENTIFIED SPEAKER: She said that
18 in her written comments (inaudible).

19 MR. JOHNSON: Right, and besides that
20 that's my experience as well. It's -- it's
21 really true even if you notice at the conference

1 on evaluation last week and even GPRA, the
2 Government Performance Results Act, which
3 requires evaluations not evaluate, so evaluation
4 is a scary, scary thing to do. But if you make
5 it a management practice, then I think you can
6 support the self-evaluative privilege. I
7 wouldn't be in favor of doing it if it's not a
8 practice.

9 MR. SWENSON: And it's not -- I think
10 the idea is not simply that, you know, okay we've
11 heard about something, do we investigate or not.
12 I think that's different.

13 MR. JOHNSON: It's different.

14 MR. GNAZZO: The DID companies have
15 been doing evaluations. As part of DID one of
16 the issues is do you -- that we have to evaluate
17 it ourselves on a yearly basis, and we do that
18 both externally and internally. We've used
19 outside auditors and we've used inside auditors
20 to evaluate every aspect of the program, and then
21 we submit that.

1 MR. SWENSON: And I think -- well, as
2 I said, I think what Lynn is saying and I think
3 what Joe said in terms of what he called
4 substantive audits, he said there's a fair amount
5 -- maybe there's some process letter. I mean,
6 did we distribute our -- did we actually train
7 people that we said we were going to train, but
8 there's not a lot of substantive auditing. You
9 know, are we -- are people actually following the
10 laws they're supposed to follow? And Lynn I
11 think was saying there's not a lot of evaluation.

12 I want to just go ahead for a second
13 go back to something that Joe said at the outset
14 because self-evaluative privilege is even
15 narrower, I think, than what Joe was proposing.
16 It seems that, for example, that there are all
17 sorts of other kinds of client's activities
18 that's healthy, beneficial, that are kind of kept
19 under raps because of a fear of disclosure. You
20 know, telling people at training to don't take
21 notes, not publicizing cases on discipline, not

1 widely sharing -- well, this is sort of an
2 evaluation issue, but not sharing the board's
3 audit reports because you're keeping to a very
4 few and perhaps under attorney-client. Don't
5 prepare a list of dos and don'ts. As Joe said
6 (inaudible), so I think the issue is --

7 MR. GNAZZO: I violate all of those.

8 MR. SWENSON: And some companies do,
9 but I think, Pat, your -- let me just try and put
10 your hat on as an Ethics Officer Association
11 director. Are you aware that some of the member
12 companies are more skittishness about issues that
13 have been admitted?

14 MR. GNAZZO: Sure, absolutely. But,
15 again, you have to go back to the argument of
16 what's the whole intent here. I mean, I'm going
17 to put dos and don'ts on a web site for antitrust
18 because I'm trying to prevent. If somebody wants
19 to use those dos and don'ts against me then --
20 I'm a big company. I can protect myself to a
21 large extent, and I have a lot of people that get

1 involved in those dos and don'ts. I've got a lot
2 of talent coming up with those dos and don'ts, so
3 I feel very good about putting dos and don'ts up.
4 But if I -- if I get sued based on it, then I get
5 sued based on it. But I am hopefully preventing
6 things from occurring, so I'm not going to stop
7 doing dos and don'ts.

8 I don't publicize public hangings. I
9 mean, we discipline people, and then when we want
10 to go out and we want to train people, we use
11 scenarios. Now the scenarios may look like what
12 actually happened, but I don't go out and say
13 that Joe or Mary did X. I will use false names
14 and I will use false companies and false
15 divisions, but I will do training based on that.
16 I have to train. I have 190 ethics officers
17 around the world. I have to train them. The
18 best way to train them is to give them scenarios,
19 give them examples of things that have happened
20 and how to investigate it. So I can't stop doing
21 that, even though Joe -- Joe is right. You make

1 yourself open, and that's the point I was trying
2 to make with respect to the road map.

3 MR. BERRY: I need to leave, but I
4 wanted to make one comment in response to Mr.
5 Johnson's comments. I don't think probably the
6 Department of Justice would disagree that -- in
7 fact, I'm certain they wouldn't. That it's very
8 important to encourage compliance programs. But
9 to give a blanket confidentiality promise would
10 raise that to the level of a (inaudible)
11 privilege or a medical privilege or the
12 attorney-client privilege and so I would -- I
13 would think that probably it doesn't rise to that
14 level, the importance of that kind of a
15 confidentiality.

16 MR. JOHNSON: I appreciate that, and I
17 anticipate that. I think the thing to -- where
18 this resurfaces kind of thing gets into is that I
19 think it may well in some ways. In other words,
20 the amount of knowledge of things that are broken
21 in organizations, the amount that actually gets

1 out is certainly a small amount. I think with a
2 little bit of privilege that would say come
3 forward and we'll keep it -- I think the amount
4 of information can more than outweigh it.

5 MR. BERRY: Well, that may well be,
6 but I think Mr. Horowitz is correct that we
7 would, you know -- someone needs to look at it
8 then and develop some numbers somehow, and I'm
9 not even sure how. But just without something to
10 hang the hat on, it would seem that it wasn't the
11 time yet for that.

12 I thank you very much, and I enjoyed
13 speaking with you.

14 MR. SWENSON: Thank you for being
15 here. I would say I think this is -- whatever
16 the outcome of this is, whatever the next steps
17 the Advisory Group might take, will be a next
18 step and not probably a leap and a bound. These
19 are pretty complicated questions. Thanks for
20 being here.

21 MR. GNAZZO: Do you have any other

1 questions of me because I --

2 MR. SWENSON: You need to go too?

3 MR. GNAZZO: I have to catch a flight.

4 MR. SWENSON: Chuck, do have anything
5 else?

6 MR. LARSON: I was just going to say
7 that, Patrick, maybe if he's the head of the
8 association, maybe a panel -- one of your annual
9 meetings of panel U.S. attorneys, it would be
10 helpful.

11 MR. GNAZZO: I would love to.

12 MR. LARSON: Because we do work with
13 confidentiality and it's life and death with big
14 time drug dealers on a regular basis. People are
15 beat up, we've got people higher. Wood chippers
16 are going to come down killing Mormons, so we
17 view it as a serious business and they would want
18 to work with any informants. We like informants.

19 MR. HOROWITZ: I was actually going to
20 jump in on those points and just say that we talk
21 about continuum of issues, and we probably have

1 the least difficulty convincing people of the
2 importance of confidentiality. Probably the
3 toughest case you have to make is for privilege
4 because, as you said, a lot doesn't favor
5 privilege. You were talking at the start -- you
6 start off with some big issues which was immunity
7 which is obviously a very significant privilege
8 in how far you go there. So I do think there is
9 serious question on gathering data on more
10 significant proposals of the Privilege Act.
11 Although, frankly, it sounded like from what most
12 of what Pat says, you're more on the
13 confidentiality, far away from the privilege
14 issue.

15 MR. GNAZZO: Just remember from a
16 government contractor's perspective, we've been
17 living under a qui tam situation for many, many
18 years. Yet, you know, if you look at most of the
19 qui tam cases, many of them -- 90 percent of them
20 the Justice Department walks away from. We have
21 strong programs where employees feel comfortable

1 about bringing things to the attention of
2 management, but we live under this world of
3 employees going outside the company and filing
4 lawsuits at any time, and we still keep our
5 programs going for that -- for the very reason
6 that we're still trying to prevent this activity
7 from occurring, illegal activity from occurring.
8 So we're accustomed to qui tams and we still have
9 strong programs and we encourage our employees to
10 come forward. They come to us because they
11 believe in the company rather than going out to
12 the Justice Department or filing a lawsuit. So
13 knowing that we live with these qui tams, we
14 still get good results from employees because we
15 do everything we can to maintain confidentiality
16 for them.

17 MR. SWENSON: You have to go. Before
18 we lost Joe, and there's no rule that says we
19 can't adjourn a little bit early. Does anybody
20 else want to add anything, ask anything of those
21 who are remaining?

1 UNIDENTIFIED SPEAKER: Do you want to
2 ask?

3 UNIDENTIFIED SPEAKER: No, I was just
4 going to say thank you.

5 MR. SWENSON: Thank you. Then why
6 don't we stand adjourned. Thanks to everybody.
7 Everybody, thanks for being here.

8 (Breakout Session adjourned 3:51 p.m.)

9

10

11

12

13

14

15

16

17

18

19

20

21

